

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

'STOP SEPSIS!' Evaluation of the WHO Global Maternal Sepsis Awareness Campaign

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036338
Article Type:	Original research
Date Submitted by the Author:	12-Dec-2019
Complete List of Authors:	<p>Brizuela, Vanessa; WHO, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research Bonet, Mercedes; World Health Organization, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research Trigo Romero, Carla Lionela; University of Sao Paulo Faculty of Medicine of Ribeirao Preto, Department of Social Medicine Abalos, E; Centro Rosarino de Estudios Perinatales Baguiya, Adama; Research Institute of Health Sciences Fawole, Adeniran O.; University of Ibadan College of Medicine Knight, Marian; University of Oxford, National Perinatal Epidemiology Unit Lumbiganon, Pisake; Khon Kaen University, Ob & Gyn Minkauskienė, Meilė; Lithuanian University of Health Sciences, Department of Obstetrics and Gynaecology Nabhan, Ashraf; Ain Shams University, Department of Obstetrics & Gynaecology Osman, Nafissa; Hospital Central de Maputo Qureshi, Zahida; University of Nairobi Department of Obstetrics and Gynecology, Souza, Joao Paulo; University of Sao Paulo Faculty of Medicine of Ribeirao Preto, Department of Social Medicine</p>
Keywords:	Maternal medicine < OBSTETRICS, PERINATOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

'STOP SEPSIS!' Evaluation of the WHO Global Maternal Sepsis Awareness Campaign

Authors and affiliations:

Vanessa Brizuela, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland. Email: brizuelav@who.int. Telephone: +41 22 791 37 40.

Mercedes Bonet, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

Carla Lionela Trigo Romero, Department of Social Medicine. Ribeirão Preto Medical School, Ribeirão Preto, Brazil.

Edgardo Abalos, Centro Rosarino de Estudios Perinatales (CREP), Rosario, Argentina.

Adama Baguiya, Research Institute for Health Sciences, Ouagadougou, Burkina Faso.

Adeniran Olubukola Fawole[†], College of Medicine, University of Ibadan, Ibadan, Nigeria.

Marian Knight, National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, United Kingdom.

Pisake Lumbiganon, Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Meilė Minkauskienė, Department of Obstetrics and Gynaecology, Lithuanian University of Health Sciences, Kaunas, Lithuania.

1
2
3 Ashraf Nabhan, Department of Obstetrics & Gynaecology, Ain Shams University, Cairo, Egypt.
4
5

6 Nafissa Bique Osman, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
7
8

9 Zahida Qureshi, Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya.
10
11

12 João Paulo Souza, Department of Social Medicine. Ribeirão Preto Medical School, Ribeirão Preto,
13
14 Brazil.
15

16
17
18 On behalf of the WHO GLOSS Research Group
19

20
21 †Deceased January 2019
22
23

24 **Correspondence to:** Vanessa Brizuela. Email: brizuelav@who.int.
25
26
27
28

29 Key words: maternal sepsis, maternal infections, awareness campaign, evaluation, multi-country
30 study
31

32 Word count: 3,655
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract** (253 words)

2 **Objective:** To evaluate changes in awareness of maternal sepsis among healthcare providers
3 resulting from the WHO global maternal sepsis study (GLOSS) awareness campaign.

4 **Design:** Independent sample pre-post intervention through online and paper-based surveys.
5 Descriptive statistics were used for campaign recognition and exposure, and odds ratio and
6 percentage change were calculated for differences in awareness, adjusting for confounders using
7 multivariate logistic regression.

8 **Setting and participants:** Healthcare providers from 398 participating facilities in 37 low-, middle-
9 , and high-income countries.

10 **Intervention:** An awareness campaign to accompany GLOSS launched three weeks prior to data
11 collection and lasting the entire study period (28 November 2017 to 15 January 2018) and beyond.

12 **Main outcome measures:** Campaign recognition and exposure, and changes in awareness.

13 **Results:** A total of 2,188 surveys were analysed: 1,155 at baseline and 1,033 at post-intervention.
14 Most survey respondents found the campaign materials helpful (94%), that they helped increase
15 awareness (90%), and that they helped motivate to act differently (88%). There were significant
16 changes with regards to: not having heard of maternal sepsis (-63.4% change, pre-post OR 0.35, 95%
17 CI 0.18-0.68) and perception of confidence in making the right decisions with regards to maternal
18 sepsis identification and management (7.3% change, pre-post OR 1.44, 95% CI 1.01-2.06).

19 **Conclusions:** Awareness raising campaigns can contribute to an increase in having heard of maternal
20 sepsis and an increase in provider perception of confidence in making correct decisions. Offering the
21 information to make accurate and timely decisions while promoting environments that enable self-
22 confidence and support could improve maternal sepsis identification and management.

23 **Strengths and limitations of this study**

- 24 • To the best of our knowledge, this is the first evaluation to describe recognition and exposure
25 as well as changes in awareness from a campaign implemented globally accompanying a
26 research study.
- 27 • Awareness campaigns can increase recognition and knowledge of maternal sepsis and
28 improve provider confidence in responding to maternal sepsis, and when accompanying a
29 multi-country study, they can benefit project outcomes.
- 30 • This evaluation was a cost-effective, feasible way in which to assess campaign effectiveness
31 among a varied and global population of healthcare providers.
- 32 • Our pre-post design methodology with no control group does not allow to discern the impact
33 of the campaign alone.
- 34 • Survey dissemination method and anonymity did not allow matching responses at pre- and
35 post-campaign; these methods were chosen to allow for responses from a large, unknown
36 population and to encourage providers to respond honestly.

37

38 INTRODUCTION

39 The global health community has recently drawn attention to the importance of sepsis and its toll on
40 global mortality and morbidity.[1-3] In 2017, the World Health Assembly approved a resolution on
41 sepsis to improve the prevention, diagnosis, and management of sepsis.[4] With updates in 2017 and
42 2018, the Surviving Sepsis Campaign has been developing guidelines for management and
43 recommended bundles of care for sepsis among adult populations since 2002.[5-7]

44 Infections and sepsis remain major causes of death and disability among women during pregnancy,
45 childbirth, postpartum, and post-abortion.[8,9] To respond to this, the Global Maternal Sepsis
46 Initiative was launched in 2016.[4,10] Building on the 2016 SEPSIS-3 definition,[11] the World
47 Health Organization (WHO) led the development of a definition for maternal sepsis as “a life-
48 threatening condition defined as organ dysfunction resulting from infection during pregnancy,
49 childbirth, postpartum, and post-abortion.”[12] And in 2017, WHO led the Global Maternal Sepsis
50 Study and Awareness Campaign (GLOSS) to assess the burden of maternal infections and sepsis, to
51 validate identification criteria for possible severe maternal infection and maternal sepsis, and to raise
52 awareness on maternal sepsis among healthcare providers working in study participating
53 facilities.[12]

54 These initiatives and calls to action all share a recommendation to increase awareness of sepsis
55 among healthcare providers, policy-makers, and the public, in pursuit of reducing the global burden
56 of sepsis.

57 Awareness raising has mostly been attempted through campaigns. These have been implemented to
58 increase knowledge, improve attitudes, or change behaviours around different health issues.[13-15]
59 Specific to sepsis, the UK Sepsis Trust heads a campaign on sepsis since 2012 and the Global Sepsis
60 Alliance leads efforts aimed at raising sepsis awareness since 2010.[16,17] However, neither of these

61 two large campaigns have been specific to maternal sepsis and to our knowledge neither has been
62 thoroughly evaluated to assess for impact in increasing awareness.

63 This evaluation looked at recognition and exposure to the GLOSS campaign materials and changes in
64 provider awareness of maternal sepsis after campaign implementation. The latter included changes
65 in knowledge on maternal sepsis and perception of enabling environments for identification and
66 management of maternal sepsis.

67 **METHODS**

68 The GLOSS campaign was designed to accompany the Global Maternal Sepsis Study with the goal of
69 raising awareness on maternal sepsis among healthcare providers working in participating facilities.

70 Details regarding study protocol, including selection of countries and facilities was published
71 elsewhere.[12] In short, GLOSS was a facility-based, one-week inception cohort study which enrolled
72 pregnant or recently pregnant women with suspected or confirmed infection at 713 healthcare
73 facilities in pre-specified geographical areas located in 52 low-, middle-, and high-income
74 countries.[12]

75 **The STOP SEPSIS! awareness campaign**

76 The campaign launch was planned for before study implementation continuing throughout data
77 collection and beyond. It was designed using existing frameworks for public information campaigns,
78 social marketing, health communication, and behaviour change.[13,18–20] The development of the
79 campaign included an overarching communication strategy using a multi-component approach
80 delivering a simple and consistent message through visually-attractive media.[21]

81 The campaign had a soft launch with an online congress on 12 September 2017 and the full campaign
82 rollout began on 06 November 2017, which included a website, printed materials, social media

1
2
3 83 messaging, press releases. While global coordination of the campaign was undertaken by WHO,
4
5 84 implementation of the campaign was the remit of GLOSS country coordinators. **Box 1** describes the
6
7 85 different actions and components that were necessary for the design and development of the *STOP*
8
9 86 *SEPSIS! awareness campaign*.

11
12
13 **Box 1.** Actions and components for the *STOP SEPSIS! awareness campaign*

- 14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- *Select a campaign lead.* A campaign lead was selected to coordinate and assist with the development of the campaign strategy and execution, and evaluation plan at a global level. This person ensured execution of each of the steps, supported the communication company and the study country coordinators in the participating countries who interacted with the providers working in the participating facilities.
 - *Agree on a budget to fund the campaign.* Funds were necessary to cover the costs of the campaign lead, the communication company, and support to countries for printing of materials. The cost of this campaign was USD 200,000.
 - *Seek the assistance of health and media communication experts.* A communication company with expertise in global health was contracted to lead the design and development of the GLOSS campaign concept and look.
 - *Decide on the minimum set of materials and activities to be developed and implemented.* With input from people in the field who would be targeted through the campaign, the decision to have posters, infographics, press release and other presentation templates, social media messaging, and a website was agreed upon. In addition, a global congress was conceived in collaboration with partners from the Global Sepsis Alliance.
 - *Develop campaign messaging, image, and logo.* A main message, tagline, and logo were designed with assistance from the communication company, content experts in maternal sepsis, and country/regional coordinators for GLOSS.
 - *Develop an evaluation plan.* Given the breadth and geographical extent of the campaign's target population an online survey was used to collect providers' knowledge, attitudes, practices at baseline and post-campaign, including additional measures of campaign recognition and exposure at post-campaign. Paper-based surveys were used on demand.
 - *Support the printing and upkeep of materials.* The campaign lead coordinated translation of all materials into five UN official languages and three additional languages as per GLOSS country coordinators' request. Participating countries were provided with funds needed to print the posters and infographics. Campaign lead was also in charge of regular upkeep of the dedicated website which includes timely news stories.
 - *Implement the campaign.* This included:
 - *WSC Spotlight Congress.* A free, online congress focusing specifically on maternal and neonatal sepsis offered in collaboration with the Global Sepsis Alliance (<https://wscspotlight.org/>). The 25 presentations given over four sessions were later made available as YouTube videos and podcasts for free, with subtitles in multiple languages.
 - *Website.* A dedicated website used both as a repository of campaign materials for free download and to disseminate news about the study (<http://srhr.org/sepsis>).
 - *Print materials.* Posters with information about the study and infographics on maternal sepsis prevention, and identification and management to be displayed in

- different areas where women with suspected or confirmed infection could be found (e.g. labour ward, patient waiting area).
- *Press releases.* Templates for announcing the objectives of the study and the campaign; countries/facilities were encouraged to engage local media for this purpose.
 - *Social media.* Campaign messaging disseminated and multiplied using social media through HRP's Twitter platform (@HRPresearch).
 - *Expand the effect of the campaign.* Countries were encouraged to take ownership over the campaign and develop additional materials and organise activities prior to the start of study data collection.

87

88 **Evaluation of the STOP SEPSIS! awareness campaign**

89 We used an independent sample pre-post intervention design through online and paper-based
90 surveys. Details regarding the definition used for awareness for this campaign, survey formulation
91 and dissemination, including analysis of baseline data have been published elsewhere.[22] Briefly, a
92 pre-campaign 32-question survey was developed to gather baseline information on healthcare
93 providers' awareness of maternal sepsis through self-reported knowledge on maternal sepsis and
94 perception of their work environments as enabling for the identification and management of
95 maternal sepsis. Knowledge was assessed through questions relating to whether respondents had
96 heard of maternal sepsis, correct identification of criteria that define maternal sepsis (infection plus
97 organ dysfunction), and identification of correct initial management of maternal sepsis and infections
98 (antibiotics and fluids) when maternal sepsis was suspected in the case vignette presented in the
99 survey. Perception of enabling environments was assessed through self-reported confidence in
100 making right decisions, reported availability of resources for correct identification and management,
101 and feeling of support from their work environments in dealing with maternal sepsis, using a five-
102 point Likert-scale. The same survey was administered at post-campaign to assess changes in
103 knowledge and perception of their environments; 14 additional questions were included in the post-
104 survey which considered respondents' recognition of and exposure to the campaign, such as
105 knowledge about the study and the campaign, message recall, engagement with social media for the

1
2
3 106 campaign, and whether the campaign materials prompted changes in behaviour. See **Appendix 1** for
4
5 107 a copy of the surveys.
6
7

8 108 Eligible respondents were healthcare providers working in GLOSS participating facilities in countries
9
10 109 that received financial support for campaign implementation (N=46); we excluded all surveys from
11
12 110 respondents that did not explicitly state that they were providers caring for women with infections
13
14 111 in healthcare facilities (e.g., hospital administrators, physical therapists, or community health
15
16 112 workers, or if the field was left blank) and from countries with less than two responses at either pre-
17
18 113 or post-campaign (N=9). See **Figure 1** for a map of all the countries included in GLOSS and in this
19
20 114 evaluation. The surveys were distributed using a snowballing technique and were available in eight
21
22 115 languages: Arabic, English, French, Italian, Portuguese, Russian, Spanish, and Vietnamese. The
23
24 116 surveys were available for over 30 days (pre-campaign between 29 September and 05 November
25
26 117 2017, post-campaign between 31 January and 11 March 2018). Weekly reminders were sent through
27
28 118 the online tool and via email to non-respondents. Targeted outreach was undertaken in countries
29
30 119 with fewer than two responses. The campaign was active between 06 November 2017 and 15 January
31
32 120 2018; however, countries were encouraged to continue to use the materials beyond GLOSS study
33
34 121 implementation. Ethical approval for GLOSS and the awareness campaign was obtained from WHO's
35
36 122 Ethics Review Committee (protocol ID A65787) and from local and facility ethics committees as
37
38 123 necessary.
39
40
41
42
43

44 124 **Data analysis**

45
46
47 125 We used descriptive analysis to provide frequencies and percentages for the characteristics of the
48
49 126 sample, knowledge and perceived enabling environments, and for all the questions relating to
50
51 127 campaign recognition and exposure. The latter was assessed through post-campaign surveys only
52
53 128 and complemented with self-reported accounts by GLOSS country coordinators. Text-based
54
55 129 responses were codified into numerical values according to common emerging themes. All Likert-
56
57
58
59
60

1
2
3 130 scale answers were dichotomized assigning a 1 to the two most favourable responses (i.e., they felt
4
5 131 *very* or *somewhat* confident about making the right decision) and 0 to the combination of remaining
6
7 132 options (*neutral*, *not very confident* or *not confident at all*). While previously we assessed
8
9 133 dichotomization using 1 to the single most favourable response (i.e., respondent felt *very confident*)
10
11 134 and a 0 to the combination of remaining options (*somewhat confident*, *neutral*, *not very confident* or
12
13 135 *not confident at all*)[22] we decided to include a more flexible definition of confidence, perception of
14
15 136 availability of resources, and feeling of support to allow for a more robust denominator that would
16
17 137 enable comparisons. See **Appendix 2** for results of the overall analysis using this second
18
19 138 dichotomization not used in this evaluation.
20
21
22

23 139 To assess impact of the campaign we conducted several analyses. First, we calculated percentage
24
25 140 change $([(\% \text{ in post} - \% \text{ in pre})/\% \text{ in pre}] \times 100)$ and estimated odds ratios (ORs) to determine
26
27 141 differences in respondent knowledge and perception of enabling environments after campaign
28
29 142 implementation relative to baseline measure for the total sample and by respondent characteristics.
30
31 143 Due to the methodology used for survey dissemination and anonymity of surveys, this was not a
32
33 144 matched sample, paired response pre-post analysis. Sensitivity analyses were conducted restricting
34
35 145 the population to facilities from which we received at least one survey response and at least two
36
37 146 responses, and to countries with more than 30 responses per country at pre- and at post-campaign
38
39 147 survey.
40
41
42

43
44 148 Second, we used multivariate logistic regression models to explore the association between
45
46 149 respondents' and facilities' characteristics at pre- and post-campaign and change in components of
47
48 150 awareness after campaign implementation. Based on analysis of baseline data and our assumptions
49
50 151 on characteristics that would be associated with levels of awareness,[22] we included the following
51
52 152 variables in the model: whether respondent was a physician, years of work experience, region where
53
54 153 the respondent worked, whether the country had implemented an *expanded* version of the campaign,
55
56
57

1
2
3 154 and whether the facility was a level III facility. Countries were considered to have implemented an
4
5 155 expanded version of the campaign if they had not only printed and displayed all posters and
6
7 156 infographics, prepared and disseminated press releases, but if they had also organized other
8
9 157 activities or developed other materials for the campaign. Since less than 20% of respondents
10
11 158 participated in the World Sepsis Congress Spotlight we did not include this variable in our models.
12
13
14 159 We looked at effect modification by examining interactions between the time of the survey (pre- or
15
16 160 post-) and each of the characteristics included in the model.
17
18

19 161 We used Pearson's χ^2 test to compare proportions and Wald's test to assess for significant differences
20
21 162 in the models including interaction terms. Logistic regression analysis was used to estimate odds
22
23 163 ratios between pre- and post-, crude and adjusted, clustering at the geographical area level. Statistical
24
25 164 significance is reported at $p < 0.05$. Stata (version 14.2, College Station, TX) was used for the analyses.
26
27
28

29 165 **Patient and public involvement**

30
31
32 166 This research was done without patient or public involvement. While the development of the
33
34 167 campaign was done with input from study regional and country coordinators, respondents to the
35
36 168 surveys were not invited to comment on the study design or to contribute to the writing of this
37
38 169 manuscript given their anonymity.
39
40

41 170 **Role of the funding source**

42
43
44
45 171 The funders of the study had no role in study design, data collection, data analysis, data
46
47 172 interpretation, or writing of this original article.
48
49

50 173 **RESULTS**

51
52 174 A total of 2,188 surveys met our inclusion criteria. Of these, 1,155 from 192 facilities were received
53
54 175 at baseline and 1,033 from 196 facilities at post-campaign. There were no significant differences in
55
56
57

176 sociodemographic characteristics between respondents at pre- and post-campaign surveys, except
 177 for a higher proportion of respondents working in a public facility at post-campaign and the higher
 178 proportion of respondents from countries where an expanded version of the campaign was
 179 implemented (**Table 1**). Responses came from the same overall countries at pre- and post-campaign.
 180 Because of the technique used for survey dissemination and because we did not know the total
 181 population of potentially exposed healthcare providers working in GLOSS participating facilities
 182 (provider turnover, rotation, and replacements is high), we were unable to calculate a response rate.
 183 However, since the campaign was implemented equally at the geographical area level, if providers
 184 remained within the study area they would have been exposed to the campaign. Results from the
 185 sensitivity analyses showed that overall findings in the sub-groups considered were consistent with
 186 the results from the complete sample (**Appendix 3**); for this reason, we used the entire sample for
 187 all subsequent analyses.

Table 1. Characteristics of respondents and the facilities in which they work at pre- and post-campaign survey (N=2,188)

Respondent characteristics	Pre-campaign (N=1,155)		Post-campaign (N= 1,033)	
	N	%	N	%
<i>Age (in years)</i>	1,147		1,020	
<31	354	31	301	30
31-40	389	34	407	40
>40	404	35	312	31
<i>Sex</i>	1,153		1,022	
Male	287	25	223	22
Female	866	75	799	78
<i>Qualification</i>	1,151		1,025	
Nurse/auxiliary nurse/midwife	440	38	456	44
Physician	561	49	456	44
Resident	150	13	113	11
<i>Years of work experience</i>	1,107		970	
<10	541	49	476	49
10-20	349	32	320	33
>20	217	20	174	18
<i>Region</i>	1,155		1,033	
Africa	224	19	226	22

	Asia	173	15	170	16
	Eastern Mediterranean	171	15	165	16
	Europe [‡]	137	12	97	9
	Latin America	450	39	375	36
	<i>Level of the facility in which respondent works</i>	<i>1,153</i>		<i>1,033</i>	
	I	127	11	166	16
	II	236	20	258	25
	III	790	69	609	59
	<i>Respondent worked in a public facility*</i>	<i>1,154</i>		<i>1,033</i>	
	Yes	937	81	928	90
	No	217	19	105	10
	<i>Country implemented an expanded version of campaign*</i>	<i>1,155</i>		<i>1,033</i>	
	Yes	705	39	533	52
	No	450	61	500	48

[‡]Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan), in line with WHO regions

* $p < 0.05$

188

189 We first present the results relating to campaign recognition and exposure and then results relating
190 to changes in knowledge and perception of respondents' work environments.

191 **Campaign recognition and exposure**

192 Campaign recognition and exposure were high among most of the post-campaign survey respondents.
193 Seventy-six percent of respondents stated they noticed the materials in their facilities; among those,
194 94% reported finding the materials helpful, 90% that the materials helped increase awareness on
195 maternal sepsis and 88% that the materials motivated them to do something differently. Only 8% of
196 respondents had used Twitter to amplify the message of the campaign (**Figure 2**). Among
197 respondents that stated that the information provided in the materials motivated them to do
198 something differently than before, 83% stated that it motivated them to suspect maternal sepsis and
199 77% to act fast. (**Figure 3**). Among respondents stating that the materials had not motivated them to

1
2
3 200 do anything differently, 45% said it was because they already knew about maternal sepsis
4
5 201 identification and management while 12% stated they had not seen the campaign materials.
6
7
8 202 Country coordinators shared anecdotal experiences of increased awareness in their facilities and the
9
10 203 implementation of changes in practice and policies because of the study and the campaign. These
11
12 204 accounts speak of a broader engagement with maternal sepsis identification and management. See
13
14
15 205 **Box 2** for some examples.

16
17
18 **Box 2. Accounts from the field***
19

20
21 *Implementation of the campaign changed the way the city's providers acted. First, it helped in*
22 *bridging the gap between academics and providers, which, in turn, helped motivate the entire staff*
23 *around the study. The campaign helped us all feel more committed with the study. And, most*
24 *importantly, it helped shed light on a problem (maternal sepsis) that we hadn't made public before.*
25 *(Cali, Colombia)*

26
27 *In (our) facility there was already a protocol for sepsis early recognition, but the campaign, as well*
28 *as the study made it come alive again. Sepsis was on everyone's eyes and mouths. The teams were very*
29 *permeable to knowledge and eager to recognize and treat sepsis immediately. (Campinas, Brazil)*

30
31 *Participation in the campaign allowed me to see that we can find cases of maternal sepsis in the most*
32 *diverse locations in a facility. And that invariably the most complex cases were those resulting from*
33 *a condition that was neglected or treated incorrectly/untimely. (Maputo, Mozambique)*

34
35 *Despite having some protocols in place, during the campaign and study we realized that these were*
36 *not sufficient to detect women with infection. This campaign was very important and helped us find*
37 *a lot of cases that might have been missed otherwise (...) We are planning on improving reporting*
38 *mechanisms of any suspected cases and supportive supervision and surveillance as a result of this*
39 *study. (Ulaanbaatar, Mongolia)*

40
41 *As a result of our participation in GLOSS, we actually committed as a Program in our 2017 Maternal*
42 *Death Review Forum to eliminate maternal sepsis as a cause of maternal death. (Manila, Philippines)*

43
44 *(Since implementing the GLOSS awareness campaign at a national level, we noticed that) we have*
45 *prioritized the identification and suspicion of maternal and neonatal sepsis in all level I facilities, in*
46 *specialized hospital care, and in the public health agenda. (Mexico City, Mexico)*

47
48
49 * These reports first appeared in a blog post on the Merck for Mothers website in April 2018:
50 <https://www.msdformothers.com/blog/assessing-addressing-maternal-sepsis.html> and in a news story on
51 WHO/HRP's website in September 2018: [https://www.who.int/reproductivehealth/maternal-sepsis-](https://www.who.int/reproductivehealth/maternal-sepsis-mexico/en/)
52 [mexico/en/](https://www.who.int/reproductivehealth/maternal-sepsis-mexico/en/)

53
54 206
55
56
57
58
59
60

207 Knowledge on maternal sepsis and perception of enabling environments

208 At pre-campaign survey, 92% of respondents (1,049/1,144) had heard of maternal sepsis. However,
 209 only 16% (109/673) of respondents were able to correctly identify the definition criteria of maternal
 210 sepsis and 45% (114/251) identified the correct management for maternal sepsis. In addition, at pre-
 211 campaign, most survey respondents stated that their work environments were enabling for maternal
 212 sepsis identification and management: 78% (897/1,155) stated that they felt confident of making
 213 right decisions, 79% (909/1,155) that they perceived resources were available, and 80%
 214 (921/1,155) that they felt supported by their facilities. See **Table 2** for overall results.

215 After campaign implementation there was a significant decrease in respondents who stated not
 216 having heard of maternal sepsis (-63.4% change; OR 0.35, 95% CI 0.18-0.68). There was also a
 217 significant increase in perceived confidence in making right decisions with regards to maternal sepsis
 218 identification and management (7.3% change; OR 1.44, 95% CI 1.01-2.06), although this level was
 219 quite high at pre-campaign (78%). There was a slight increase in respondents' ability to identify the
 220 correct management when maternal sepsis was suspected after the implementation of the campaign,
 221 but this was not statistically significant (30.8% change; OR 1.76, 95% CI 0.73-4.21). See **Appendix**
 222 **4a and 4b** for these results according to respondent and facility characteristics.

Table 2. Respondent knowledge on maternal sepsis and perception of enabling environments for maternal sepsis identification and management at pre- and post-campaign and changes after campaign implementation (N=2,188)

	Pre-campaign n/N (%)	Post-campaign n/N (%)	Pre-post cOR [‡] [95% CI] [¶]	Percentage change %
<i>Knowledge on maternal sepsis</i>				
Had not heard of maternal sepsis ^(A)	95/1,144 (8.3)	31/1,021 (3.0)	0.35* [0.18-0.68]	-63.4
Correctly identified the two criteria to define maternal sepsis ^(B)	109/673 (16.2)	74/647 (11.4)	0.67 [0.43-1.17]	-29.4
Correctly identified management of sepsis when maternal sepsis was suspected ^(C)	114/251 (45.4)	142/239 (59.4)	1.76 [0.73-4.21]	30.8

Perception of enabling environment for maternal sepsis identification and management

Confident of making right decisions	897/1,155 (77.7)	861/1,033 (83.4)	1.44* [1.01-2.06]	7.3
Resources available to make right decisions	909/1,155 (78.7)	814/1,033 (78.8)	1.01 [0.68-1.49]	0.1
Supported by facility in making right decisions	921/1,155 (79.7)	840/1,033 (81.3)	1.11 [0.80-1.54]	2.0

cOR: crude odds ratio; CI: confidence interval

Percentage change: $[(\% \text{ in post} - \% \text{ in pre})/\% \text{ in pre}] \times 100$

‡Refers to odds ratio between pre- and post-campaign; OR calculated clustering at the geographical area level

*‡reference group: pre-campaign; * $p < 0.05$*

^(A) Responded NO to the question "have you ever heard of the term maternal sepsis?"

^(B) Answered INFECTION and ORGAN DYSFUNCTION to the question: "what two criteria best describe maternal sepsis?"

^(C) Answered FLUIDS and ANTIBIOTICS to the question: "what would be the first two things a woman should receive," when the respondent answered INFECTION/SEPSIS to the question: "what would you first think could be causing her to feel this way?"

223

224 After controlling for respondent and facility characteristics, being a physician, having less than 10

225 years of experience, and working in a level III facility were associated with decreased odds of not

226 having heard of maternal sepsis at pre-campaign (**Table 3**). Respondents from facilities that had

227 implemented an expanded version of the campaign were more likely to have heard of maternal sepsis

228 and identify the correct management of maternal sepsis at post-campaign. Respondents with less

229 than 10 years of experience were more likely to have heard of maternal sepsis at pre-campaign, but

230 there were no differences across providers with different years of experience after the campaign.

231 Physicians were more likely to respond that they felt confident in making the right decisions at post-

232 campaign, while being a physician and having more than 20 years of experience had a significant

233 interaction with time of the survey with regards to perception of availability of resources and support

234 from their facilities. At pre- and post-campaign, respondents with 20 years or more of experience

235 were more likely to perceive availability of resources for making right decisions and to feel supported

236 by their facilities and these differences between groups were significant after the campaign (**Table**

1
2
3 237 4). No differences in the perception of enabling environments were seen among respondents from
4
5 238 facilities that had implemented an expanded version of the campaign.
6
7

8 239
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2

3 **Table 3. Knowledge on maternal sepsis adjusted for respondents' characteristics (N=2,188)**

	Had not heard about maternal sepsis					Correctly identified the two criteria to define maternal sepsis					Correctly identified management of sepsis when maternal sepsis was suspected				
	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test
Respondent characteristics	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>
Physician	0.29*	0.10-0.85	0.58	0.17-1.93	0.108	1.78	0.80-3.95	3.85*	1.54-9.60	0.175	2.07*	1.24-3.45	2.81*	1.08-7.30	0.583
Years of work experience															
<10	0.50*	0.26-0.96	1.57	0.77-3.18	0.035	1.08	0.60-1.96	0.86	0.55-1.34	0.352	0.86	0.53-1.40	0.61	0.30-1.23	0.775
10-20	1 (ref)		1 (ref)			1 (ref)		1 (ref)			1 (ref)		1 (ref)		
>20	1.21	0.61-2.38	0.73	0.19-2.87		1.17	0.59-2.30	1.50*	1.02-2.21		1.59	0.60-4.22	0.9	0.30-2.71	
Country implemented an expanded version of campaign	1.54	0.46-5.12	0.21*	0.06-0.78	0.004	1.18	0.53-2.65	0.86	0.31-2.34	0.281	2.78*	1.01-7.59	8.02*	2.03-31.73	0.437
Respondent worked in a level III facility	0.45*	0.21-0.96	1.79	0.59-5.42	0.006	1.63	0.77-3.45	2.80*	1.32-5.94	0.314	2.10	0.85-5.16	1.14	0.43-3.02	0.406

23[†]Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan), in line with WHO regions

24[‡]Countries were considered to have implemented an expanded version of the campaign if they had not only printed and displayed all posters and infographics, prepared and disseminated press releases, but if they had also organized other activities or developed other materials for the campaign.

26[§]Adjusting for whether respondent was a physician, years of work experience, region, whether the country implemented an expanded version of the campaign, and whether respondent worked in a level III facility, clustering at the geographical area level

28^{||}aOR: adjusted odds ratio; CI: confidence interval; Wald's test used to assess for differences in the models including interaction terms; **p*<0.05

30 240

32 241

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 4. Perception of enabling environments for maternal sepsis identification and management adjusted for respondents' characteristics (N=2,188)

Respondent characteristics	Confident of making right decisions					Resources available to make right decisions					Supported by facility in making right decision				
	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test
	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>
<i>Physician</i>	1.02	0.64-1.64	1.69*	1.19-2.40	0.246	0.81	0.55-1.20	1.39	0.99-1.95	0.021	0.78	0.55-1.09	1.26	0.83-1.92	0.017
<i>Years of work experience</i>															
<10	0.74	0.51-1.09	0.88	0.63-1.22	0.025	0.63*	0.41-0.97	0.82	0.53-1.27	0.014	0.70	0.46-1.06	0.95	0.69-1.30	0.038
10-20	1 (ref)		1 (ref)			1 (ref)		1 (ref)			1 (ref)		1 (ref)		
>20	1.20	0.76-1.91	2.54*	1.38-4.64		1.66*	1.08-2.54	2.48*	1.49-4.13		1.60*	1.07-2.40	2.78*	1.84-4.20	
<i>Country implemented an expanded version of campaign</i>	0.65	0.36-1.16	0.91	0.56-1.48	0.605	1.00	0.52-1.94	1.57	0.85-2.88	0.241	1.32	0.86-2.03	1.37	0.90-2.07	0.092
<i>Respondent worked in a level III facility</i>	0.90	0.55-1.47	0.64*	0.41-1.00	0.581	1.39	0.86-2.23	1.27	0.79-2.04	0.255	0.88	0.53-1.46	1.18	0.67-2.07	0.116

*Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan), in line with WHO regions

Countries were considered to have implemented an expanded version of the campaign if they had not only printed and displayed all posters and infographics, prepared and disseminated press releases, but if they had also organized other activities or developed other materials for the campaign.

Adjusting for whether respondent was a physician, years of work experience, region, whether the country implemented an expanded version of the campaign, and whether respondent worked in a level III facility, clustering at the geographical area level

aOR: adjusted odds ratio; CI: confidence interval; Wald's test used to assess for differences in the models including interaction terms; **p*<0.05

242

1
2
3 243 **DISCUSSION**
4
5

6 244 To the best of our knowledge, this is the first study to assess impact of an awareness campaign aimed
7
8 245 at healthcare providers and implemented at a global level where pre-campaign and post-campaign
9
10 246 data were collected in addition to measures relating to campaign recognition and exposure. Most
11
12 247 healthcare providers stated that the campaign helped increase awareness of maternal sepsis and
13
14 248 motivated them to do something differently, particularly to suspect maternal sepsis and act faster.
15
16 249 Reports from the field also support this finding that exposure to the campaign increased sensitization
17
18 250 to maternal infections and sepsis. Moreover, most survey respondents had heard of maternal sepsis
19
20 251 even before campaign implementation; after the campaign this increased significantly. Although
21
22 252 most respondents perceived their enabling environments in a positive way before campaign
23
24 253 implementation, there was an increase in respondent confidence to make the right decisions
25
26 254 regarding maternal sepsis identification and management after campaign implementation.
27
28
29
30

31 255 The *STOP SEPSIS! awareness campaign* implementation was effective with regards to respondents'
32
33 256 recognition of and exposure to the campaign; other campaign evaluations have used these measures
34
35 257 to positively assess short-term impact of campaigns.[23–25] Furthermore, consistent and repeat
36
37 258 exposure to campaign messaging have shown to increase awareness;[13] while exposure was only
38
39 259 measured over the course of this evaluation period corresponding to the intended implementation
40
41 260 period of the campaign, the fact that most respondents stated the campaign raised awareness is a
42
43 261 promising trend in the right direction.
44
45
46

47 262 Overall knowledge about maternal sepsis increased from pre- to post-campaign implementation
48
49 263 among respondents to our survey with regards to having heard about maternal sepsis. Our finding
50
51 264 that overall knowledge increased is supported by existing literature that suggests that campaigns can
52
53 265 increase knowledge on a specific topic among healthcare providers[14,26,27] as well as among the
54
55 266 general population.[23,28,29] The fact that there was a slight increase in identifying the correct
56
57
58
59
60

1
2
3 267 management of maternal sepsis is important. Research has shown that knowing what is needed to
4
5 268 manage maternal sepsis correctly and early management of maternal sepsis are critical to
6
7 269 implementing any changes in providers' behaviour and improving maternal health
8
9 270 outcomes.[6,30,31] The GLOSS awareness campaign was associated with reducing differences among
10
11 271 groups of healthcare providers depending on their qualifications or years of experience. This speaks
12
13 272 to the importance of including healthcare providers with different qualifications and years of
14
15 273 experience in awareness-raising efforts.

16
17
18
19 274 We found there were overall increases in respondent confidence in making right decisions about
20
21 275 maternal sepsis identification and management, but no significant changes with regards to overall
22
23 276 respondent perception of availability of necessary resources and feeling supported by their facilities.
24
25 277 Evidence shows that confidence can not only affect clinical performance;[32] but also that high levels
26
27 278 of confidence among healthcare providers can have a positive impact on patients' perception of
28
29 279 experience of care.[33] However, the change in perception of availability of resources and support
30
31 280 limited to physicians and more experienced providers raises a broader question on actions that
32
33 281 facilities need to take to empower all healthcare workers in feeling that they have the necessary
34
35 282 resources and feel supported to provide quality care. This is especially important if we consider that
36
37 283 a more restrictive definition of enabling environments results in much lower overall levels of
38
39 284 perceived confidence, perception of availability of resources, and feeling of support. These findings
40
41 285 are a call to hospital administrators and policy-makers to foster enabling environments and secure
42
43 286 availability and access to life-saving resources.

44
45
46
47
48 287 Sepsis awareness is gaining traction on global agendas;[4,10,16] this is supported by evidence from
49
50 288 two studies looking at internet searches on sepsis,[34,35] meaning increases resulting from this
51
52 289 campaign could be responding to natural trends or other factors. It is also possible that awareness
53
54 290 was raised by having participated in the research study and not necessarily because of the campaign;

1
2
3 291 disentangling the effect of the campaign from that of the implementation of the research study was
4
5 292 impossible. Understanding whether any of these changes are sustained over time would provide us
6
7 293 with further information on the lasting effects of the campaign.
8
9

10 294 Literature shows that while a campaign can help in raising awareness, it is insufficient in allowing for
11
12 295 changes in behaviour.[13,19] While behaviour change is important in impacting population-level
13
14 296 health, it is one of many components needed to make significant improvements; evidence from this
15
16 297 study, similar to others, highlight the need for health systems improvements such as availability of
17
18 298 critical resources and support to improve maternal outcomes.[36] Assessing the impact that
19
20 299 increased awareness resulting from a campaign has on behaviour change would provide us with
21
22 300 supporting evidence that campaigns can help in improving health outcomes.
23
24
25

26 301 This study has some limitations. First, we used a pre-post design methodology with no control group
27
28 302 which does not allow to discern the impact of the campaign alone. Second, the method used to
29
30 303 disseminate the survey and the fact that surveys were anonymous made it impossible to match
31
32 304 responses at pre- and post-campaign. Surveys were anonymous to encourage providers to respond
33
34 305 and remove potential response bias. However, it is to note that characteristics of participants at pre-
35
36 306 and post-campaign were similar. Third, because implementation of the campaign was left up to
37
38 307 country coordinators, campaign fidelity was only assessed through healthcare provider self-report
39
40 308 at post-campaign surveys. Fourth, this evaluation was restricted to the duration of the study follow-
41
42 309 up period, limiting our knowledge of lasting impact of the campaign, which was beyond the goal of
43
44 310 this activity. However, our findings suggest that campaigns can have at least short-term effects on
45
46 311 provider's knowledge and confidence. The positive perception of the campaign materials is
47
48 312 encouraging. And fifth, since baseline data was collected after the soft launch of the campaign, the
49
50 313 effect of the campaign may have been minimized because awareness had already been increased
51
52
53
54
55
56
57
58
59
60

1
2
3 314 through exposure to the online congress as well as other global activities on sepsis conducted by
4
5 315 other groups. However, we know that less than 20% of respondents participated in the congress.
6
7

8 316 Our findings have implications for both practice and research. On the one hand, there appear to be
9
10 317 benefits to coupling large multi-country studies with awareness campaigns. A campaign targeting
11
12 318 healthcare providers can promote their engagement with research studies being conducted,
13
14 319 potentially improving study outcomes. There is also evidence that including an awareness campaign
15
16 320 creates an environment prime to implementing changes to clinical practice as per research study
17
18 321 protocol. On the other hand, there is a clear need for additional research to identify lasting effects of
19
20 322 awareness campaigns, especially as global initiatives focus on increasing awareness on maternal
21
22 323 health issues.
23
24

25
26 324 A campaign designed to raise awareness among healthcare providers working in facilities
27
28 325 participating in a global research study was associated with an increase in having heard of maternal
29
30 326 sepsis, as well as increased provider perception of confidence in making correct decisions. Offering
31
32 327 healthcare providers with the information to make accurate and timely decisions while promoting
33
34 328 environments that enable self-confidence and support could improve maternal sepsis identification
35
36 329 and management, which can ultimately have an impact on maternal health outcomes.
37
38
39

40 330

41 331 **FIGURES**

42
43
44 332 **Figure 1.** Countries participating in GLOSS (N=52)

45
46
47
48
49 333 **Figure 2.** Measures of campaign exposure in percentages (N=1,033)

1
2
3 334 **Figure 3.** Responses when answering YES to the question “Did the information provided in the
4
5 335 materials motivate you to do something differently than before?” (N=668). (Respondents were able
6
7 336 to check as many response options as needed)
8
9

10
11 337 **APPENDICES**
12

13
14 338 **Appendix 1.** Global Maternal Sepsis Study – Pre- and Post- Campaign Surveys
15

16
17 339 **Appendix 2.** Respondent perception of enabling environments for maternal sepsis identification and
18
19 340 management at pre- and post-campaign and changes after campaign implementation, limiting to
20
21 341 most favourable responses (N=2,188)
22

23
24 342 **Appendix 3.** Changes in respondent knowledge and perception of enabling environments after
25
26 343 campaign implementation among different sub-groups
27

28
29 344 **Appendix 4.** Changes in respondent knowledge and perception of enabling environments after
30
31 345 campaign implementation according to respondent and facility characteristics
32
33

34
35 346 **SUPPLEMENTARY FILES**
36

37
38 347 **Supplementary file 1.** Published protocol for the Global Maternal Sepsis Study and Awareness
39
40 348 Campaign
41

42
43 349 **Supplementary file 2.** Strobe checklist
44
45

46
47 350
48
49 351 **Acknowledgments:** The authors wish to thank Khalid Yunis for his contributions to the development
50
51 352 of the campaign, Soe Soe Thwin and Cristina Cuesta for their assistance in the planning and review
52
53 353 of statistical analyses, and all the respondents to the online and paper-based survey. The authors
54
55
56
57

1
2
3 354 would also like to acknowledge the contribution and lifelong achievements of co-author Bukola
4
5 355 Fawole, who passed away prior to the publication of this article.
6
7
8 356

9
10 357 **Contributors:** The evaluation plan and first draft of this original article was conceived by VB. MB
11
12 358 provided substantial contributions to the data planning and analysis and first versions of this
13
14 359 manuscript. The idea for the inclusion of an awareness campaign was first conceived by JPS. CLTR,
15
16 360 JPS, and EA provided additional feedback on first draft and data analysis. All authors read and
17
18 361 approved the final version. VB, MB, and CLTR had full access to all the data and VB has final
19
20 362 responsibility for the decision to submit for publication.
21
22
23 363

24
25 364 **Funding:** This work was supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special
26
27 365 Programme of Research, Development and Research Training in Human Reproduction (HRP),
28
29 366 Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
30
31 367 (project A65787), Merck Sharp & Dohme Corp., a wholly owned subsidiary of Merck and Co., Inc.
32
33 368 (Kenilworth, NJ USA), through its Merck for Mothers program, and the United States Agency for
34
35 369 International Development (USAID) Grant number GHA-G-00-09-00003. The views of the funding
36
37 370 bodies have not influenced the content of this manuscript.
38
39
40 371

41
42
43 372 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
44
45 373 www.icmje.org/coi_disclosure.pdf and declare: support from WHO/RHR, Merck for Mothers, and
46
47 374 USAID for the submitted work; VB, MB, and JPS were employed by WHO at the time of the study; no
48
49 375 other relationships or activities that could appear to have influenced the submitted work.
50
51
52 376

1
2
3 377 **Ethical approval:** Ethical approval for the entire study, including the awareness campaign, was
4
5 378 obtained from WHO's Ethics Review Committee in Geneva, Switzerland (protocol ID A65787) for a
6
7 379 multi-site, multi-country project. A legend was included in the survey stating that response to the
8
9 380 survey implied consent to participate; respondents could recuse themselves at any point during the
10
11 381 survey, including skipping and not answering certain questions.
12

13
14 382

15
16
17 383 **Data sharing:** All enquiries regarding the data and analyses can be made to the corresponding
18
19 384 author.

20
21
22 385 **Transparency:** The lead author (VB) affirms that the manuscript is an honest, accurate, and
23
24 386 transparent account of the study being reported; that no important aspects of the study have been
25
26 387 omitted; and that any discrepancies from the study as planned have been explained.
27

28
29 388

30
31 389 **Disclosure:** This article represents the views of the named authors only and does not represent the
32
33 390 views of the World Health Organization
34

35
36
37 391 **World Health Organization Global Maternal Sepsis Study Research Group (in alphabetical**
38
39 392 **order)**

40
41 393 AFGHANISTAN: Mohammad Iqbal Aman, Bashir Noormal. ARGENTINA: Virginia Díaz, Marisa
42
43 394 Espinoza, Julia Pasquale. BELGIUM: Charlotte Leroy, Kristien Roelens, Griet Vandenberghe. BENIN:
44
45 395 M. Christian Urlyss Agossou, Sourou Goufodji Keke, Christiane Tshabu Aguemon. BOLIVIA: Patricia
46
47 396 Soledad Apaza Peralta, Víctor Conde Altamirano, Rosalinda Hernández Muñoz. BRAZIL: José
48
49 397 Guilherme Cecatti, Carolina Ribeiro do Valle. BURKINA FASO: Vincent Batiene, Kadari Cisse, Henri
50
51 398 Gautier Ouedraogo. CAMBODIA: Cheang Kannitha, Lam Phirun, Tung Rathavy. CAMEROON: Elie
52
53 399 Simo, Pierre-Marie Tebeu, Emah Irene Yakana. COLOMBIA: Javier Carvajal, María Fernanda Escobar,
54
55
56
57
58
59
60

- 1
2
3 400 Paula Fernández. DENMARK: Lotte Berdiin Colmorn, Jens Langhoff-Roos. ECUADOR: Wilson Mereci,
4
5 401 Paola Vélez. EGYPT: Yasser Salah Eldin, Alaa Sultan. ETHIOPIA: Abdulfetah Abdulkadir Abdosh, Alula
6
7 402 M. Teklu, Dawit Worku. GHANA: Richard Adanu, Philip Govule, Charles Noora Lwanga. GUATEMALA:
8
9 403 William Enrique Arriaga Romero, María Guadalupe Flores Aceituno. HONDURAS: Carolina Bustillo,
10
11 404 Rigoberto Castro, Bredy Lara. INDIA: Vijay Kumar, Vanita Suri, Sonia Trikha. ITALY: Irene Cetin,
12
13 405 Serena Donati, Carlo Personeni. KAZAKHSTAN: Guldana Baimussanova, Saule Kabylova, Balgyn
14
15 406 Sagyndykova. KENYA: George Gwako, Alfred Osoi, Zahida Qureshi. KYRGYZSTAN: Raisa
16
17 407 Asylbasheva, Aigul Boobekova, Damira Seksenbaeva. LEBANON: Faysal El Kak, Saad Eddine Itani,
18
19 408 Sabina Abou Malham. LITHUANIA: Meilė Minkauskienė, Diana Ramašauskaitė. MALAWI: Owen
20
21 409 Chikhwaza, Luis Gadama, Eddie Malunga. MALI: Haoua Dembele, Hamadoun Sangho, Fanta Eliane
22
23 410 Zerbo. MEXICO: Filiberto Dávila Serapio, Nazarea Herrera Maldonado, Juan I. Islas Castañeda.
24
25 411 REPUBLIC OF MOLDOVA: Tatiana Cauaus, Ala Curteanu, Victor Petrov. MONGOLIA: Yadamsuren
26
27 412 Buyanjargal, Seded Khishgee, Bat-Erdene Lkhagvasuren. MOROCCO: Bouchra Assarag, Amina
28
29 413 Essolbi, Rachid Moulki. MOZAMBIQUE: Zara Jaze, Arlete Mariano, Nafissa Osman. MYANMAR: Hla
30
31 414 Mya Thway Einda, Thae Maung Maung, Khaing Nwe Tin. NEPAL: Tara Gurung, Amir Babu Shrestha,
32
33 415 Sangeeta Shrestha. NETHERLANDS: Kitty Bloemenkamp, Marcus J. Rijken, Thomas Van Den Akker.
34
35 416 NICARAGUA: María Esther Estrada, Néstor J. Pavón Gómez. NIGERIA: Olubukola Adesina, Chris
36
37 417 Aimakhu, Bukola Fawole. PAKISTAN: Rizwana Chaudhri, Saima Hamid, M. Adnan Khan. PERU: María
38
39 418 del Pilar Huatuco Hernández, Nelly M. Zavaleta Pimentel. PHILIPPINES: Maria Lu Andal, Zenaida Dy
40
41 419 Recidoro, Carolina Paula Martin. ROMANIA: Mihaela Budianu, Lucian Pușcașiu. SENEGAL: Léopold
42
43 420 Diouf, Dembo Guirassy, Philippe Marc Moreira. SLOVAKIA: Miroslav Borovsky, Ladislav Kovac,
44
45 421 Alexandra Kristufkova. SOUTH AFRICA: Sylvia Cebekhulu, Laura Cornelissen, Priya Soma-Pillay.
46
47 422 SPAIN: Vicenç Cararach, Marta López, María José Vidal Benedé. SRI LANKA: Hemali Jayakody, Kapila
48
49 423 Jayaratne, Dhammica Rowel. SUDAN: Mohamed Elsheikh, Wisal Nabag, Sara Omer. TAJIKISTAN:
50
51 424 Victoria Tsoy, Urunbish Uzakova, Dilrabo Yunusova. THAILAND: Thitiporn Siriwachirachai,
52
53
54
55
56
57
58
59
60

1
2
3 425 Thumwadee Tangsiriwatthana. UNITED KINGDOM: Catherine Dunlop, Marian Knight, David
4
5 426 Lissauer. URUGUAY: Aquilino M. Pérez, Jhon Roman, Gerardo Vitureira. VIET NAM: Dinh Anh Tuan,
6
7 427 Luong Ngoc Truong, Nghiem Thi Xuan Hanh. ZIMBABWE: Mugove Madziyire, Thulani Magwali,
8
9 428 Stephen Munjanja. Regional Coordinators: Edgardo Abalos, Adama Baguiya, Mónica Chamillard,
10
11 429 Bukola Fawole, Marian Knight, Seni Kouanda, Pisake Lumbiganon, Ashraf Nabhan, Ruta
12
13 430 Nadisaukiene. Technical Advisory Group: Linda Bartlett; Fernando Bellissimo-Rodrigues; Shevin T.
14
15 431 Jacob; Sadia Shakoor; Khalid Yunis. Data management and analysis: Liana Campodónico, Cristina
16
17 432 Cuesta, Hugo Gamero, Daniel Giordano. WHO coordinating Unit: Fernando Althabe, Mercedes Bonet,
18
19 433 Vanessa Brizuela, A. Metin Gülmezoglu, João Paulo Souza.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 Reinhart K, Daniels R, Kissoon N, *et al.* Recognizing Sepsis as a Global Health Priority — A WHO Resolution. *N Engl J Med* 2017;**377**:414–7. doi:10.1056/NEJMp1707170
- 2 Rudd KE, Kissoon N, Limmathurotsakul D, *et al.* The global burden of sepsis: barriers and potential solutions. *Crit Care* 2018;**22**. doi:10.1186/s13054-018-2157-z
- 3 Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. *J Glob Health* 2012;**2**. doi:10.7189/jogh.02.010404
- 4 WHO. Improving the prevention, diagnosis and management of sepsis. World Health Assembly: 2017. http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_R7-en.pdf?ua=1
- 5 Surviving Sepsis Campaign | History. <http://www.survivingsepsis.org/About-SSC/Pages/History.aspx> (accessed 20 Aug 2017).
- 6 Rhodes A, Evans LE, Alhazzani W, *et al.* Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med* 2017;**43**:304–77. doi:10.1007/s00134-017-4683-6
- 7 Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. *Intensive Care Med* 2018;**44**:925–8. doi:10.1007/s00134-018-5085-0
- 8 Say L, Chou D, Gemmill A, *et al.* Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health* 2014;**2**:e323–e333.
- 9 Kassebaum NJ, Barber RM, Bhutta ZA, *et al.* Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* 2016;**388**:1775–812. doi:10.1016/S0140-6736(16)31470-2
- 10 The Global Maternal and Neonatal Sepsis Initiative: a call for collaboration and action by 2030. *Lancet Glob Health* 2017;**0**. doi:10.1016/S2214-109X(17)30020-7
- 11 Singer M, Deutschman CS, Seymour CW, *et al.* The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;**315**:801. doi:10.1001/jama.2016.0287
- 12 Bonet M, Souza JP, Abalos E, *et al.* The global maternal sepsis study and awareness campaign (GLOSS): study protocol. *Reprod Health* 2018;**15**:16. doi:10.1186/s12978-017-0437-8
- 13 Randolph W, Viswanath K. Lessons Learned from Public Health Mass Media Campaigns: Marketing Health in a Crowded Media World. *Annu Rev Public Health* 2004;**25**:419–37.
- 14 Pittet D, Hugonnet S, Harbarth S, *et al.* Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. *The Lancet* 2000;**356**:1307–12. doi:10.1016/S0140-6736(00)02814-2
- 15 Glanz K, Rimer BK, Lewis, editors. *Health Behavior and Health Education: Theory, Research, and Practice*. 3rd ed. San Francisco: : Jossey-Bass 2002.

- 16 Global Sepsis Alliance. <https://www.global-sepsis-alliance.org/> (accessed 27 Feb 2019).
- 17 UK Sepsis Trust. Sepsis Trust. <https://sepsistrust.org/> (accessed 27 Feb 2019).
- 18 Weiss JA, Tschirhart M. Public Information Campaigns as Policy Instruments. *J Policy Anal Manage* 1994;**13**:82. doi:10.2307/3325092
- 19 Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. *The Lancet* 2010;**376**:1261–71. doi:10.1016/S0140-6736(10)60809-4
- 20 *Making Health Communication Programs Work*. National Cancer Institute 2004. <https://www.cancer.gov/publications/health-communication/pink-book.pdf> (accessed 11 Jan 2017).
- 21 O'Connor M, McGowan K, Jolivet RR. An awareness-raising framework for global health networks: lessons learned from a qualitative case study in respectful maternity care. *Reprod Health* 2019;**16**. doi:10.1186/s12978-018-0662-9
- 22 Brizuela V, Bonet M, Souza JP, *et al*. Factors influencing awareness of healthcare providers on maternal sepsis: a mixed-methods approach. *BMC Public Health* 2019;**19**:683. doi:10.1186/s12889-019-6920-0
- 23 Kaufman MR, Harman JJ, Smelyanskaya M, *et al*. “Love me, parents!”: impact evaluation of a national social and behavioral change communication campaign on maternal health outcomes in Tanzania. *BMC Pregnancy Childbirth* 2017;**17**:305. doi:10.1186/s12884-017-1470-x
- 24 Evans WD, Uhrig J, Davis K, *et al*. Efficacy methods to evaluate health communication and marketing campaigns. *J Health Commun* 2009;**14**:315–30. doi:10.1080/10810730902872234
- 25 Bazzo S, Black D, Mitchell K, *et al*. ‘Too Young To Drink’. An international communication campaign to raise public awareness of fetal alcohol spectrum disorders. *Public Health* 2017;**142**:111–5. doi:10.1016/j.puhe.2016.08.001
- 26 Al-Dorzi HM, Cherfan A, Al-Harbi S, *et al*. Knowledge of thromboprophylaxis guidelines pre- and post-didactic lectures during a venous thromboembolism awareness day at a tertiary-care hospital. *Ann Thorac Med* 2013;**8**:165–9. doi:10.4103/1817-1737.114298
- 27 Pattinson RC, Bergh A-M, Makin J, *et al*. Obstetrics knowledge and skills training as a catalyst for change. *S Afr Med J* 2018;**108**:748. doi:10.7196/SAMJ.2018.v108i9.13073
- 28 Vallone D, Cantrell J, Bennett M, *et al*. Evidence of the Impact of the truth FinishIt Campaign. *Nicotine Tob Res* 2018;**20**:543–51. doi:10.1093/ntr/ntx119
- 29 Alaqeel A, Kamalmaz H, Abou Al-Shaar H, *et al*. Evaluating the initial impact of the Riyadh Epilepsy Awareness Campaign. *Epilepsy Behav* 2015;**52**:251–5. doi:10.1016/j.yebeh.2015.09.010
- 30 Robson W, Beavis S, Spittle N. An audit of ward nurses’ knowledge of sepsis. *Nurs Crit Care* 2007;**12**:86–92. doi:10.1111/j.1478-5153.2007.00210.x

- 1
2
3 31 Gaieski D, Mikkelsen M, Band R, *et al*. Impact of time to antibiotics on survival in patients with
4 severe sepsis or septic shock in whom early goal-directed therapy was initiated in the
5 emergency department*. *Crit Care Med* 2010;**38**:1045–53.
6 doi:10.1097/CCM.0b013e3181cc4824
7
- 8 32 Cheng ER, Nelson CC, Leung-Strle P, *et al*. Nutrition provider confidence in the Massachusetts
9 Childhood Obesity Research Demonstration (MA-CORD) study. *Prev Med Rep* 2019;**13**:289–92.
10 doi:10.1016/j.pmedr.2019.01.010
11
- 12 33 Owens KM, Keller S. Exploring workforce confidence and patient experiences: A quantitative
13 analysis. *Patient Exp J* 2018;**5**:10.
14
- 15 34 Jabaley CS, Blum JM, Groff RF, *et al*. Global trends in the awareness of sepsis: insights from
16 search engine data between 2012 and 2017. *Crit Care Lond Engl* 2018;**22**:7.
17 doi:10.1186/s13054-017-1914-8
18
- 19 35 Savelkoel J, Claushuis TAM, van Engelen TSR, *et al*. Global impact of World Sepsis Day on digital
20 awareness of sepsis: an evaluation using Google Trends. *Crit Care* 2018;**22**.
21 doi:10.1186/s13054-018-1981-5
22
- 23 36 van Den Broek, Nynke, Ameh C, Madaj B, *et al*. Effects of emergency obstetric care training on
24 maternal and perinatal outcomes: a stepped wedge cluster randomised trial in South Africa.
25 *BMJ Glob Health* Published Online First: 2019. doi:10.1136/ bmjgh-2019-001670
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Countries participating in GLOSS (N=52). Key: teal: countries included in the GLOSS STOP SEPSIS! awareness campaign evaluation (N=37); green: countries eligible for the evaluation but from which 1 or less responses received for the evaluation (N=9); yellow: countries that participated in GLOSS but did not implement the awareness campaign (N=6)




Figure 2. Measures of campaign exposure in percentages (N=1,033)




Figure 3. Responses when answering YES to the question "Did the information provided in the materials motivate you to do something differently than before?" (N=668). (Respondents were able to check as many response options as needed)

Appendix 1. Global Maternal Sepsis Study – Pre- and Post-Campaign Surveys

GLOSS Pre-Campaign Survey

This online survey is part of the activities set forth for a global study on maternal morbidity and mortality. This study is being conducted in approximately 50 countries across the globe, including your own, and it is coordinated by the World Health Organization and the healthcare facility where you work.

As part of this study, we want to learn more from healthcare providers about how you identify and manage women with complications during pregnancy, childbirth, postpartum, or post-abortion. The survey includes a number of questions on your knowledge, attitudes, and practices around maternal and neonatal health. This is not a test; this is an opportunity to let us know your thoughts and experience on the topic as a healthcare provider in one of the hospitals participating in the study.

This survey is voluntary, and your answers will be kept confidential, and you can choose whether to leave some questions unanswered. General information about you, your position, and geographical location will be collected to help us categorize respondents only but will not be used to identify you in particular. You are free to provide this information at the end of the survey.

After the study, and only if you agree, a second online survey will be sent to you via email. For this reason, we will ask you to provide an email address so that we can ensure delivery of the second survey. You will be free to decide to participate in this second survey too. Results of these surveys will be published in a peer-reviewed journal without attributing responses to any specific person or institution.

The completion of this survey implies your consent to participate.

If you have any question about the survey, please contact Ms Vanessa Brizuela (brizuelav@who.int)

I. Knowledge and attitudes

The following questions will ask that you respond according to your current role, competences, and skills depending on your training and background. That is, according to these, you may be the person triaging, prescribing, diagnosing, treating. Bear this in mind when responding.

1. What are the main conditions causing death and disability among women during pregnancy and/or childbirth in your hospital? Check all that apply [abortion-related complications, chronic/pre-existing disease, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other: please specify]
2. Case vignettes:

Case A: A 25-year-old 32-week pregnant woman comes to your facility brought by a family member saying she is feeling unwell. Her companion reports that she seems a bit disoriented and feverish. Without any further diagnostic testing or triaging:

 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials, ART), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
3. Case B: A recently pregnant woman comes to your facility complaining that she has abdominal pain and shortness of breath. Without any further diagnostic testing or triaging:
 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials, ART), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
4. How confident do you feel that you are capable of making the right decision in a case like the one above? [very confident, somewhat confident, neutral, not too confident, not confident at all]
5. How would you qualify the availability of resources in the facility where you work to help you make the right decisions? [always available, somewhat available, neutral, not always available, not available at all].
6. How supported do you feel by the facility in which you work to make the right decision in a case like the one above? [very supported, somewhat supported, neutral, not very supported, unsupported].
7. How well does this statement describe your facility: "The facility where I work doesn't let me handle cases like the one described above." [very well, somewhat well, indifferent, somewhat incorrectly, completely incorrectly]

- 1
2
3
4
5
6
7
8
9
10
8. Of the following, which do you think are the greatest barriers in making a right, and timely decision in your facility? Check up to two options. [I'm afraid of making a mistake, I've never seen cases like these, my supervisor doesn't let me make them, not sure I know the correct signs, we don't have a way to triage/treat/manage cases like these in my hospital, other]
 9. Does the hospital you work in have protocols in place for dealing with cases like the one described above? [yes/no/don't know]

11 DO NOT ALLOW GOING BACK AFTER THIS QUESTION

- 12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
10. Have you ever heard of the term maternal sepsis? [yes/no]
 11. If yes, how did you hear about this? Check all that apply [pre-service training, in-service training, public health campaign, colleagues, media (TV/radio/newspaper), other: please specify].
 12. What two criteria best describe maternal sepsis? Check two options [abnormal white cell count, altered mental status, elevated heart rate, excessively rapid respiration, fever, infection, low blood pressure, organ dysfunction, other]
 13. What supplies/commodities are essential to effectively identify sepsis among women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [blood culture, blood pressure apparatus, diagnostic imaging, laboratory (haematology/biochemistry), rapid test for infectious disease, serum lactate measurement, thermometer, urine output measurement, other]
 14. What supplies/commodities are essential to effectively manage sepsis in women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [antibiotics, blood transfusions, fluids, intensive care/high-dependency unit, other antimicrobials (e.g. antimalarials, ART), oxygen, urine output measurement, other]

34 II. Context

- 35
36
37
38
39
40
41
42
43
44
45
46
47
15. How many women are affected by maternal sepsis in your facility every year? Give your best estimate (a whole number), given your experience in the facility [Text box]
 16. How many neonates are affected by neonatal sepsis in the first week of life in your facility? Give your best estimate (a whole number), given your experience in the facility. [Text box]
 17. How many deliveries occur every year, on average, in your facility? Give your best estimate (a whole number). [Text box]
 18. Have you ever received specific training in how to manage women who present with signs of infection while pregnant, during childbirth, postpartum or post-abortion? [yes/no/can't remember]

48 III. Personal information

49
50 Remember! These data are collected for categorization purposes only. Your information is
51 confidential and you will not be identified in any future publications on this study.
52

- 53
54
55
56
19. Age range
 20. Gender: [male, female, other]

- 1
2
3 21. Qualification: [nurse, midwife, physician/medical doctor, resident/physician in training,
4 community health worker, social worker, other: please specify].
5
6 22. Years of work experience in current setting: [years|months]
7
8 23. Total years of work experience (since completing your training): [number entry/2-digit max]
9
10 24. Place of work: [list of countries]
11
12 25. Location (of current or main place of work): [urban/rural]
13
14 26. Name of facility & address [Text box]
15
16 27. Facility type (of current or main place of work): [Clinic, Health centre, Maternity hospital,
17 Regional/Provincial hospital, District hospital, Other hospital, other]
18
19 28. Facility management (of current or main place of work): [private, public, social insurance,
20 NGO, other]
21
22 29. Did you participate in this year's World Sepsis Congress Spotlight on Maternal and Neonatal
23 Sepsis (held on 12 September 2017)? [yes/no]
24
25

26 **IV. Future contacts**

- 27
28 30. The global maternal study and awareness campaign would like to contact you at a future date
29 for a follow-up on this survey. If you agree to being contacted again, please provide us with
30 your email address.
31

32 Your contact details will be securely stored by the WHO staff person working on the study for one
33 year. You can contact us to modify or suppress your information at any time. To do so, please contact
34 Ms Vanessa Brizuela (brizuelav@who.int).
35

- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- I agree.
 - I do not agree

Please provide us with your email address [text box]

Thank you very much for participating in this survey! Your responses are extremely valuable to us in our efforts to improve the health of women and newborns.

GLOSS Post-Campaign Survey

This online survey is part of the activities set forth for a global study on maternal morbidity and mortality. This study is being conducted in approximately 50 countries across the globe, including your own, and it is coordinated by the World Health Organization and the healthcare facility where you work. As part of this study, we want to learn more from healthcare providers about how you identify and manage women with certain conditions during pregnancy, childbirth or postpartum or post- abortion.

A few months ago, you received a similar survey from us. At that point we asked that you provide us with an email address so that we could send you a follow-up questionnaire. We will ask again that you respond to a number of questions on your knowledge, attitudes, and practices around maternal and neonatal health. This is not a test; this is an opportunity to let us know your thoughts and experience on the topic as a healthcare provider in one of the hospitals participating in the study.

This survey is voluntary, and your answers will be kept confidential, and you can choose whether to leave some questions unanswered. General information about you, your position, and geographical location will be collected to help us categorize respondents only but will not be used to identify you in particular. You are free to provide this information at the end of the survey. Results of these surveys will be published in a peer-reviewed journal without attributing responses to any specific person or institution.

The completion of this survey implies your consent to participate.

If you have any question about the survey, please contact Ms Vanessa Brizuela (brizuelav@who.int)

I. General knowledge and attitudes

The following questions will ask that you respond according to your current role, competences, and skills depending on your training and background. According to these, you may be the person triaging, prescribing, diagnosing, treating. Bear this in mind when responding.

1. What are the main conditions causing death and disability among women during pregnancy and/or childbirth in your hospital? Check all that apply [abortion-related complications, chronic/pre-existing disease, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other: please specify]
2. Case vignettes:

Case A: A 25-year-old 32-week pregnant woman comes to your facility brought by a family member saying she is feeling unwell. Her companion reports that she seems a bit disoriented and feverish. Without any further diagnostic testing or triaging:

 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
3. Case B: A recently pregnant woman comes to your facility complaining that she has abdominal pain and shortness of breath. Without any further diagnostic testing or triaging:
 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials, ART), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
4. How confident do you feel that you are capable of making the right decision in a case like the one above? [very confident, somewhat confident, indifferent/neutral, not too confident, not confident at all]
5. How would you qualify the availability of resources in the facility where you work to help you make the right decisions? [always available, somewhat available, indifferent/neutral, not always available, not available at all].
6. How supported do you feel by the facility in which you work to make the right decision in a case like the one above? [very supported, somewhat supported, neutral, not very supported, unsupported].
7. How well does this statement describe your facility: "The facility where I work doesn't let me handle cases like the one described above." [very well, somewhat well, indifferent/neutral, somewhat incorrectly, completely incorrectly]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
8. Of the following, which do you think are the greatest barriers in making a right, and timely decision in your facility? Check one option (the one most accurate to your situation). [not sure I know the correct signs, I'm afraid of making a mistake, my supervisor doesn't let me make them, we don't have a way to triage/treat/manage cases like these in my hospital, I've never seen cases like these, There are no barriers to making a right and timely decision in my facility, other]
 9. Does the hospital you work in have protocols in place for dealing with cases like the one described above? [yes/no/don't know]

14 DO NOT ALLOW GOING BACK AFTER THIS QUESTION

- 15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
10. Have you ever heard of the term maternal sepsis? [yes/no]
 11. If yes, how did you hear about this? Check all that apply [pre-service training, in-service training, colleagues, public health campaign, media (TV/radio/newspaper), other: please specify].
 12. What two criteria best describe maternal sepsis? Check two options [abnormal white cell count, altered mental status, elevated heart rate, excessively rapid respiration, fever, infection, low blood pressure, organ dysfunction, other]
 13. What supplies/commodities are essential to effectively identify sepsis among women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [blood culture, blood pressure apparatus, diagnostic imaging, laboratory (haematology/biochemistry), rapid test for infectious disease, serum lactate measurement, thermometer, urine output measurement, other]
 14. What supplies/commodities are essential to effectively manage sepsis in women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [antibiotics, blood transfusions, fluids, intensive care/high-dependency unit, other antimicrobials (e.g. antimalarials, ART), oxygen, urine output measurement, other]

37 **II. Context**

- 38
39
40
41
42
43
44
45
46
47
48
49
15. How many women are affected by maternal sepsis in your facility every year? Give your best estimate (a whole number), given your experience in the facility [Text box]
 16. How many neonates are affected by neonatal sepsis in the first week of life in your facility? Give your best estimate (a whole number), given your experience in the facility. [Text box]
 17. How many deliveries occur every year, on average, in your facility? Give your best estimate (a whole number). [Text box]
 18. Have you ever received specific training in how to manage women who present with signs of infection while pregnant, during childbirth, postpartum or post-abortion? [yes/no/can't remember]

50
51 **III. Campaign**

- 52
53
54
55
56
19. Did you notice any materials in your facility that related to maternal and neonatal sepsis? [yes/no] [if no go to question 27]

- 1
2
3 20. If yes, where did you see them? Check all that apply [labour ward, antenatal ward, postnatal
4 ward, emergency room/department, ICU/high dependency room, patient waiting area, other:
5 please specify]
6
7 21. If yes, what materials did you see? Check all that apply [informational posters about the study,
8 graphic materials with information about maternal sepsis, campaign website, social media,
9 press releases, none of the above].
10
11 a. Did you ever visit the website? [yes/no/N/A]
12 b. Did you ever tweet/re-tweet a message about the campaign? [yes/no/I don't use Twitter]
13 22. What were the main messages of these materials? Check all that apply ["stop sepsis", "think
14 sepsis", "right care, right now", "sepsis is life-threatening but when caught early and treated
15 promptly it can be stopped", "just ask, could it be sepsis?", "a world free of sepsis", "together,
16 we can stop maternal sepsis", "stop sepsis save lives", "surviving sepsis", none of the above]
17
18 23. Did you find the materials and messaging helpful? [yes/no]
19
20 a. If yes, why? Check all that apply [they provided information about maternal sepsis, they
21 invited me to act, they mentioned things I did not know, they helped explain the study to
22 me, they were visually appealing, they were in a language I could understand, other]
23 b. If no, why not? Check all that apply [they didn't provide any new information, I didn't
24 know what to do, the message was confusing, they were difficult to understand, they were
25 in a language I don't speak/read, they had too much text, they had too many images, the
26 colours didn't work in our hospital, they were unappealing, other]
27
28 24. Did the materials help you identify cases of women with infection or sepsis? [yes/no]
29
30 25. Did the information provided in the materials motivate you to do something differently than
31 before? [yes/no]
32
33 a. If yes, in what way? Check all that apply [to suspect maternal sepsis among women
34 presenting with specific signs, to act fast when I think a woman could have sepsis, to
35 implement health measures to prevent sepsis, to talk about sepsis with others, to learn
36 more about sepsis, other: please specify]
37 b. If no, why not? Please explain [text box]
38
39 26. In your opinion, did the materials help to increase awareness about maternal sepsis in your
40 facility? [yes/no]
41
42 27. Did you know that your facility participated in a global maternal sepsis study? [yes/no]
43
44 28. Did you know that your facility participated in an awareness campaign for the global
45 maternal sepsis study? [yes/no]
46

IV. Personal information

47 Remember! These data are collected for categorization purposes only. Your information is
48 confidential and you will not be identified in any future publications on this study.
49

- 50 29. Age range [18-25; 26-30; 31-40; 41-50; 51-60; 60+]
51 30. Gender: [male, female, other]
52 31. Qualification: [community health worker, midwife, nurse, physician/medical doctor,
53 resident/physician in training, social worker, student, physical therapist, auxiliary nurse,
54 other: please specify].
55
56

- 1
2
3 32. Years of work experience in current setting: [years | months]
4 33. Total years of work experience (since completing your training): [2-digit max]
5 34. Place of work: [list of countries]
6 35. Location (of current or main place of work): [urban/rural]
7 36. Name of facility and address [text entry]
8 37. Facility type (of current or main place of work): [Clinic, Health centre, Maternity hospital,
9 Regional/Provincial hospital, District hospital, Other hospital, other]
10 38. Facility management (of current or main place of work): [private, public, social insurance,
11 NGO, other]
12 39. Did you participate in the World Sepsis Congress Spotlight on Maternal and Neonatal Sepsis
13 (held on 12 September 2017)? [yes/no]
14
15
16

17 V. Future contacts

18
19 We might be interested in contacting you in the future with more information about this study or to
20 get further information about your responses to this survey. Please provide us with your email
21 address below if you agree with this.
22
23

- 24 I agree.
25 I do not agree
26

27 Your contact details will be securely stored by the WHO staff person working on the Global Maternal
28 and Neonatal Initiative for one year. You can contact us to modify or suppress your information at
29 any time. To do so, please contact Ms Vanessa Brizuela (brizuelav@who.int)
30
31

- 32 40. Please type your email address below [text entry]
33
34
35

36 Thank you very much for participating in this survey! Your responses are extremely valuable to us in
37 our efforts to improve the health of women and babies.
38

39 Please visit <http://srhr.org/sepsis> for more information about the study, the campaign, and maternal
40 sepsis.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Appendix 2. Respondent perception of enabling environments for maternal sepsis identification and management at pre- and post-campaign and changes after campaign implementation, limiting to most favourable responses (N=2,188)

	Pre-campaign n/N (%)	Post-campaign n/N (%)	Pre-post cOR [‡] [95% CI] [¶]	Percentage change %
<i>Perception of enabling environment for maternal sepsis identification and management</i>				
Very confident of making right decisions	390/1,155 (33.8)	395/1,033 (38.2)	1.21* [1.05-1.41]	13.2
Resources always available to make right decisions	443/1,155 (38.4)	386/1,033 (37.4)	0.96 [0.68-1.35]	-2.6
Very supported by facility in making right decisions	503/1,155 (43.6)	438/1,033 (42.4)	0.95 [0.67-1.37]	-2.6

cOR: crude odds ratio; CI: confidence interval; OR calculated clustering at the country level

Percentage change: [(% in post - % in pre)/% in pre]x100

**Refers to odds ratio between pre- and post-campaign; ¶reference group: pre-campaign; *p<0.05*

Responses were dichotomized as follows: a 1 was assigned to the most favourable response (i.e., they felt very confident about being capable of making the right decision) and a 0 to a combination of all the remaining options (i.e., somewhat confident, neutral, not very confident or not confident at all)

Appendix 3. Changes in respondent knowledge and perception of enabling environments after campaign

implementation among different sub-groups: [1] sample restricted to ≥1 response per facility at pre- and post-campaign; [2] sample restricted to ≥2 responses per facility at pre- and post-campaign; [3] sample restricted to countries with >30 responses at pre- or post-campaign

	Full sample (N=2,188)		Restricted sample ≥1 response per facility (N=1,872)		Restricted sample ≥2 responses per facility (N=1,645)		Restricted sample >30 responses per country (N=1,680)	
	Pre-post OR [‡] [95% CI] [†]	% change	Pre-post OR [‡] [95% CI] [†]	% change	Pre-post OR [‡] [95% CI] [†]	% change	Pre-post OR [‡] [95% CI] [†]	% change
<i>Knowledge on maternal sepsis</i>								
Have not heard of maternal sepsis	0.35* [0.18-0.68]	-63.4	0.36* [0.17-0.77]	-61.82	0.45* [0.22-0.93]	-53.58	0.34* [0.15-0.79]	-63.29
Correctly identified the two criteria to define maternal sepsis	0.67 [0.43-1.03]	-29.4	0.63 [0.39-1.01]	-33.19	0.57* [0.34-0.93]	-38.76	0.57* [0.33-0.98]	-39.46
Correctly identified management of sepsis when maternal sepsis was suspected	1.76 [0.73-4.21]	30.8	1.58 [0.58-4.30]	24.05	1.53 [0.51-4.62]	21.70	1.70 [0.51-5.72]	24.89
<i>Perception of enabling environment for maternal sepsis identification and management</i>								
Confident of making right decisions	1.44* [1.01-2.06]	7.3	1.36 [0.97-1.90]	6.39	1.33 [0.94-1.88]	6.34	1.45 [0.95-2.22]	7.99
Resources available to make right decisions	1.01 [0.68-1.49]	0.1	1.12 [0.76-1.66]	2.32	1.12 [0.72-1.74]	2.23	0.92 [0.57-1.50]	-1.62
Supported by facility in making right decisions	1.11 [0.80-1.54]	2.0	1.21 [0.84-1.73]	3.44	1.19 [0.81-1.76]	3.45	0.99 [0.69-1.44]	-0.11

OR: odds ratio; CI: confidence interval; percentage change = $[(\% \text{ in post} - \% \text{ in pre}) / \% \text{ in pre}] \times 100$

[‡]Refers to odds ratio between pre- and post-campaign, OR calculated clustering at the country level; [†]reference group pre-campaign; * $p < 0.05$

Appendix 4a. Changes in respondent knowledge after campaign implementation according to respondent and facility characteristics (N= 2,188)

Respondent characteristics	Had not heard about maternal sepsis					Correctly identified the two criteria to define maternal sepsis					Correctly identified management of sepsis when maternal sepsis was suspected							
	Pre-campaign (N=1,144)		Post-campaign (N=1,021)		OR [95% CI]†	% change	Pre-campaign (N=673)		Post-campaign (N= 647)		OR [95% CI]†	% change	Pre-campaign (N=251)		Post-campaign (N=239)		OR [95% CI]†	% change
	n	%	N	%		%	n	%	n	%		%	n	%	n	%		%
Overall	95	8	31	3	0.35* [0.23-0.52]	-63.4	109	16	74	11	0.67 [0.43-1.03]	-29.4	114	45	142	59	1.76 [0.73-4.21]	30.8
Qualification	1,141		1,013				670		645				250		235			
Nurse/midwife	74	17	16	4	0.18* [0.10-0.33]	-79.2	14	6	8	3	0.48 [0.20-1.14]	-50.3	24	28	41	46	2.13 [0.53-8.47]	61.3
Physician	16	3	10	2	0.77 [0.26-2.31]	-22.6	72	21	55	19	0.87 [0.55-1.38]	-10.3	55	50	75	67	2.06* [1.09-3.91]	35.1
Resident	4	3	4	4	1.36 [0.13-14.31]	34.3	23	27	11	15	0.48 [0.11-2.11]	-44.4	34	63	25	76	1.84 [0.49-6.90]	20.3
Years of experience	1,098		963				642		607				242		229			
<10	20	4	14	3	0.79 [0.28-2.24]	-19.9	58	18	32	11	0.54 [0.28-1.02]	-41.3	67	48	72	58	1.50 [0.40-5.58]	21.2
10-20	36	10	8	3	0.22* [0.10-0.50]	-75.9	28	15	24	12	0.76 [0.44-1.33]	-21.0	31	47	44	66	2.16* [1.04-4.49]	39.8
>20	26	12	4	2	0.17* [0.08-0.38]	-81.0	22	16	16	16	0.95 [0.53-1.69]	-4.4	13	37	21	57	2.22 [0.72-6.87]	52.8
Region	1,144		1,021				673		647				251		239			
Africa	14	6	4	2	0.27* [0.15-0.49]	-71.6	18	15	19	15	1.04 [0.46-2.31]	3.1	30	53	46	69	1.97 [0.95-4.08]	30.5
Asia	11	7	9	5	0.83 [0.25-2.76]	-15.7	7	5	7	6	1.06 [0.42-2.65]	5.7	4	14	8	23	1.85 [0.37-9.21]	65.8
Eastern Mediterranean	58	44	13	8	0.16* [0.09-0.31]	-81.7	2	3	8	9	3.19 [1.04-9.78]	200.0	2	12	10	45	6.25 [0.88-44.14]	286.5
Europe‡	7	5	2	2	0.39 [0.07-2.23]	-59.7	27	38	12	27	0.63* [0.41-0.96]	-27.3	5	12	4	27	1.60 [0.77-3.33]	126.8
Latin America	5	1	3	1	0.72 [0.07-7.77]	-27.9	55	20	28	11	0.49 [0.22-1.08]	-45.8	73	12	74	74	1.87 [1.17-20.42]	529.3

Country implemented an expanded version of campaign	1,144	1,021	673	647	251	239												
Yes	74	11	13	3	0.23* [0.16-0.32]	-75.2	75	19	37	12	0.58 [0.32-1.05]	-37	92	53	105	76	2.77 [0.88-8.69]	42
No	21	5	18	3	0.71 [0.35-1.45]	-27.6	34	12	37	11	0.89 [0.52-1.53]	-10	22	28	37	38	1.50 [0.51-4.40]	32
Respondent worked in a level III facility	1,144	1,021	673	647			251	239										
Yes	23	3	16	3	0.91 [0.38-2.18]	-8.5	87	18	58	15	0.80 [0.45-1.41]	-17.1	104	51	108	65	1.77 [0.51-6.10]	27.0
No	72	20	15	4	0.15* [0.08-0.28]	-82.3	22	11	16	6	0.51 [0.25-1.03]	-46.3	10	21	34	47	3.31* [1.54-7.12]	123.6

[#]Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan)

OR: odds ratio, OR calculated clustering at the country level; CI: confidence interval; Percentage change= [(% in post - % in pre)/% in pre]x100

[†]Reference group: pre-campaign

Where n represents the frequency and N the denominator (i.e. n= the number of respondents with a specific characteristic who answered correctly, N= the total number of persons who answered that question)

Appendix 4b. Changes in respondent perception of enabling environments after campaign implementation according to respondent and facility characteristics

Respondent characteristic	Confident of making right decisions					Resources available to make right decisions					Supported by facility in making right decisions							
	Pre-campaign (N=1,155)		Post-campaign (N=1,033)		OR [95% CI] †	% change	Pre-campaign (N=1,155)		Post-campaign (N=1,033)		OR [95% CI] †	% change	Pre-campaign (N=1,155)		Post-campaign (N=1,033)		OR [95% CI] †	% change
	n	%	n	%		%	n	%	n	%		%	N	%	n	%		%
Overall	897	78	861	83	1.44* [1.01-2.06]	7.3	909	79	814	79	1.01 [0.68-1.49]	0.1	921	80	840	81	1.11 [0.80-1.54]	2.0
Qualification	1,151		1,025				1,151		1,025				1,151		1,025			
Nurse/midwife	355	81	371	81	1.05 [0.56-1.96]	0.8	356	81	336	74	0.66 [0.34-1.28]	-8.9	367	83	347	76	0.63* [0.41-0.98]	-8.8
Physician	440	78	395	87	1.78* [1.23-2.57]	10.4	445	79	387	85	1.46* [1.17-1.82]	7.0	448	80	393	86	1.57* [1.12-2.22]	7.9
Resident	100	67	87	77	1.67 [0.97-2.88]	15.5	105	70	86	76	1.37 [0.77-2.42]	8.7	104	69	95	84	2.33* [1.24-4.38]	21.3
Years of experience	1,107		970				1,107		970				1,107		970			
<10	409	76	389	82	1.44 [0.99-2.10]	8.1	416	77	379	80	1.17 [0.80-1.73]	3.6	424	78	390	82	1.25 [0.86-1.83]	4.5
10-20	284	81	264	83	1.08 [0.73-1.59]	1.4	277	79	239	75	0.77 [0.52-1.13]	-5.9	280	80	248	78	0.85 [0.59-1.23]	-3.4
>20	179	82	160	92	2.43* [1.13-5.21]	11.5	187	86	153	88	1.17 [0.72-1.91]	2.0	188	87	158	91	1.52 [0.93-2.49]	4.8
Region	1,155		1,033				1,155		1,033				1,155		1,033			
Africa	189	84	198	88	1.31 [0.76-2.26]	3.8	158	71	157	69	0.95 [0.73-1.24]	-1.5	176	79	173	77	0.89 [0.63-1.26]	-2.6
Asia	128	74	145	85	2.04* [1.17-3.55]	15.3	134	77	150	88	2.18* [1.72-2.76]	13.9	137	79	151	89	2.09* [1.59-2.74]	12.2
Eastern Mediterranean	131	77	115	70	0.70* [0.64-0.77]	-9.0	109	64	84	51	0.59* [0.49-0.71]	-20.1	108	63	97	59	0.83 [0.61-1.14]	-6.9
Europe‡	97	71	77	79	1.59 [0.89-2.82]	12.1	112	82	83	86	1.32 [0.80-2.20]	4.7	112	82	88	91	2.18* [1.54-3.09]	11.0
Latin America	352	78	326	87	1.85* [1.14-3.01]	11.1	396	88	340	91	1.32 [0.68-2.57]	3.0	388	86	331	88	1.20 [0.59-2.44]	2.4

Country implemented an expanded version of campaign	1,155	1,033	1,155	1,033	1,155	1,033	1,155	1,033										
Yes	531	75	398	80	1.28 [0.76-2.15]	5.7	554	79	375	75	0.82 [0.45-1.48]	-4.6	567	80	391	78	0.87 [0.53-1.43]	-2.8
No	366	81	463	87	1.52* [1.00-2.29]	6.8	355	79	439	82	1.25 [0.83-1.89]	4.4	354	79	449	84	1.45* [1.03-2.05]	7.1
Respondent worked in a level III facility	1,155	1,033	1,155	1,033	1,155	1,033	1,155	1,033										
Yes	608	77	508	83	1.51* [1.10-2.05]	8.4	646	82	516	85	1.24 [0.85-1.79]	3.6	640	81	518	85	1.33 [0.95-1.87]	5.0
No	289	79	353	83	1.31 [0.77-2.22]	5.1	263	72	298	70	0.92 [0.62-1.36]	-2.5	281	77	322	76	0.94 [0.71-1.25]	-1.4

#Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan)

OR: odds ratio, OR calculated clustering at the country level; CI: confidence interval; Percentage change= $[(\% \text{ in post} - \% \text{ in pre})/\% \text{ in pre}] \times 100$

†Reference group: pre-campaign

Where n represents the frequency and N the denominator (i.e. n= the number of respondents with a specific characteristic who answered correctly, N= the total number of persons who answered that question)

STROBE Statement - 'STOP SEPSIS!': An evaluation of the WHO global maternal sepsis study awareness campaign (Brizuela et al)

	Item No	Recommendation	Page in manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	5-6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls (c) <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	9
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-11
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine	8-10 8-10

		subgroups and interactions	
		(c) Explain how missing data were addressed	Tables 1, 2, 3, and 4
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Not applicable
		(e) Describe any sensitivity analyses	10
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Tables 1, 2, 3 and 4
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9; table 1, figure 1
		(b) Indicate number of participants with missing data for each variable of interest	Tables 1, 2, 3, and 4
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Not applicable
Outcome data	15*	<i>Changes in awareness</i> —Report numbers of outcome events or summary measures	14-15, tables 2, 3, and 4
		<i>Campaign recognition and exposure</i> —Report numbers of outcome events or summary measures	13-14; figures 2 and 3
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	16; tables 3 and 4
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10, 15-16; appendices 2 & 3
Discussion			
Key results	18	Summarise key results with reference to study objectives	19
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	21-22
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19-22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Generalisability	21	Discuss the generalisability (external validity) of the study results	22
------------------	----	---	----

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11 and 24
---------	----	---	-----------

For peer review only

BMJ Open

Early evaluation of the 'STOP SEPSIS!' WHO Global Maternal Sepsis Awareness Campaign implemented for healthcare providers in 46 low- middle- and high-income countries

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036338.R1
Article Type:	Original research
Date Submitted by the Author:	01-Apr-2020
Complete List of Authors:	Brizuela, Vanessa; WHO, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research Bonet, Mercedes; World Health Organization, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research Trigo Romero, Carla Lionela; University of Sao Paulo Faculty of Medicine of Ribeirao Preto, Department of Social Medicine Abalos, E; Centro Rosarino de Estudios Perinatales Baguiya, Adama; Research Institute of Health Sciences Fawole, Adeniran O.; University of Ibadan College of Medicine Knight, Marian; University of Oxford, National Perinatal Epidemiology Unit Lumbiganon, Pisake; Khon Kaen University, Ob & Gyn Minkauskienė, Meilė; Lithuanian University of Health Sciences, Department of Obstetrics and Gynaecology Nabhan, Ashraf; Ain Shams University, Department of Obstetrics & Gynaecology Osman, Nafissa; Hospital Central de Maputo Qureshi, Zahida; University of Nairobi Department of Obstetrics and Gynecology, Souza, Joao Paulo; University of Sao Paulo Faculty of Medicine of Ribeirao Preto, Department of Social Medicine
Primary Subject Heading:	Global health
Secondary Subject Heading:	Global health, Obstetrics and gynaecology, Public health
Keywords:	Maternal medicine < OBSTETRICS, PERINATOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Early evaluation of the 'STOP SEPSIS!' WHO Global Maternal Sepsis Awareness Campaign**
4 **implemented for healthcare providers in 46 low- middle- and high-income countries**
5
6
7

8 **Authors and affiliations:**
9

10
11 Vanessa Brizuela, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research,
12 Development and Research Training in Human Reproduction (HRP), Department of Reproductive
13 Health and Research, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland. Email:
14 brizuelav@who.int. Telephone: +41 22 791 37 40.
15
16
17
18
19

20
21 Mercedes Bonet, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research,
22 Development and Research Training in Human Reproduction (HRP), Department of Reproductive
23 Health and Research, World Health Organization, Geneva, Switzerland.
24
25
26
27

28 Carla Lionela Trigo Romero, Department of Social Medicine. Ribeirão Preto Medical School, Ribeirão
29 Preto, Brazil.
30
31
32

33
34 Edgardo Abalos, Centro Rosarino de Estudios Perinatales (CREP), Rosario, Argentina.
35
36

37 Adama Baguiya, Research Institute for Health Sciences, Ouagadougou, Burkina Faso.
38
39

40 Adeniran Olubukola Fawole[†], College of Medicine, University of Ibadan, Ibadan, Nigeria.
41
42

43 Marian Knight, National Perinatal Epidemiology Unit, Nuffield Department of Population Health,
44 University of Oxford, United Kingdom.
45
46
47

48 Pisake Lumbiganon, Department of Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen
49 University, Khon Kaen, Thailand.
50
51
52

1
2
3 Meilė Minkauskienė, Department of Obstetrics and Gynaecology, Lithuanian University of Health
4 Sciences, Kaunas, Lithuania.
5
6

7
8 Ashraf Nabhan, Department of Obstetrics & Gynaecology, Ain Shams University, Cairo, Egypt.
9

10
11 Nafissa Bique Osman, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
12

13
14 Zahida Qureshi, Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya.
15

16
17 João Paulo Souza, Department of Social Medicine. Ribeirão Preto Medical School, Ribeirão Preto,
18 Brazil.
19
20

21
22
23 On behalf of the WHO GLOSS Research Group
24

25
26 †Deceased January 2019
27

28
29 **Correspondence to:** Vanessa Brizuela. Email: brizuelav@who.int.
30
31

32
33
34 Key words: maternal sepsis, maternal infections, awareness campaign, evaluation, multi-country
35 study
36
37

38 Word count: 3,722
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

1 **Abstract** (268 words)

2 **Objective:** To evaluate changes in awareness of maternal sepsis among healthcare providers
3 resulting from the WHO global maternal sepsis study (GLOSS) awareness campaign.

4 **Design:** Independent sample pre-post intervention through online and paper-based surveys
5 available for over 30 days before campaign rollout (pre) and after study data collection (post).
6 Descriptive statistics were used for campaign recognition and exposure, and odds ratio and
7 percentage change were calculated for differences in awareness, adjusting for confounders using
8 multivariate logistic regression.

9 **Setting and participants:** Healthcare providers from 398 participating facilities in 37 low-, middle-
10 , and high-income countries.

11 **Intervention:** An awareness campaign to accompany GLOSS launched three weeks prior to data
12 collection and lasting the entire study period (28 November 2017 to 15 January 2018) and beyond.

13 **Main outcome measures:** Campaign recognition and exposure, and changes in awareness.

14 **Results:** A total of 2,188 surveys were analysed: 1,155 at baseline and 1,033 at post-intervention.
15 Most survey respondents found the campaign materials helpful (94%), that they helped increase
16 awareness (90%), and that they helped motivate to act differently (88%). There were significant
17 changes with regards to: not having heard of maternal sepsis (-63.4% change, pre-post OR 0.35, 95%
18 CI 0.18-0.68) and perception of confidence in making the right decisions with regards to maternal
19 sepsis identification and management (7.3% change, pre-post OR 1.44, 95% CI 1.01-2.06).

20 **Conclusions:** Awareness raising campaigns can contribute to an increase in having heard of maternal
21 sepsis and an increase in provider perception of confidence in making correct decisions. Offering the

1
2
3 22 information to make accurate and timely decisions while promoting environments that enable self-
4
5 23 confidence and support could improve maternal sepsis identification and management.
6
7

8 24 **Strengths and limitations of this study**
9

- 10 25 • This study presents the results of an evaluation of a global awareness campaign which
11
12 26 accompanied a research study implemented in 46 countries.
13
14 27 • This evaluation was a cost-effective, feasible way in which to assess campaign effectiveness
15
16 28 among a varied and global population of healthcare providers.
17
18 29 • Our pre-post design using anonymous surveys with no control group does not allow to
19
20 30 discern the impact of the campaign alone or matching pre- and post- campaign responses.
21
22 31 • Campaign fidelity was only assessed through healthcare provider self-report at post-
23
24 32 campaign surveys.
25
26 33 • This evaluation was restricted to the duration of the study follow-up period limiting
27
28 34 understanding of long-term impact.
29
30
31
32
33
34
35

36 INTRODUCTION

37 The global health community has recently drawn attention to the importance of sepsis and its toll on
38 global mortality and morbidity.[1-3] In 2017, the World Health Assembly approved a resolution on
39 sepsis to improve the prevention, diagnosis, and management of sepsis.[4] With updates in 2017 and
40 2018, the Surviving Sepsis Campaign has been developing guidelines for management and
41 recommended bundles of care for sepsis among adult populations, not specific to pregnant or
42 recently pregnant women, since 2002.[5-7]

43 Infections and sepsis remain major causes of death and disability among women during pregnancy,
44 childbirth, postpartum, and post-abortion.[8,9] To respond to this, the Global Maternal Sepsis
45 Initiative was launched in 2016.[4,10] Building on the 2016 SEPSIS-3 definition,[11] the World
46 Health Organization (WHO) led the development of a definition for maternal sepsis as “a life-
47 threatening condition defined as organ dysfunction resulting from infection during pregnancy,
48 childbirth, postpartum, and post-abortion.”[12] And in 2017, WHO led the Global Maternal Sepsis
49 Study and Awareness Campaign (GLOSS) to assess the burden of maternal infections and sepsis, to
50 validate identification criteria for possible severe maternal infection and maternal sepsis, and to raise
51 awareness on maternal sepsis among healthcare providers working in study participating
52 facilities.[12]

53 These initiatives and calls to action all share a recommendation to increase awareness of sepsis
54 among healthcare providers, policy-makers, and the public, in pursuit of reducing the global burden
55 of sepsis.

56 Awareness raising has mostly been attempted through campaigns. These have been implemented to
57 increase knowledge, improve attitudes, or change behaviours around different health issues.[13-15]
58 Specific to sepsis, the UK Sepsis Trust heads a campaign on sepsis since 2012 and the Global Sepsis

1
2
3 59 Alliance leads efforts aimed at raising sepsis awareness since 2010.[16,17] However, neither of these
4
5 60 two large campaigns have been specific to maternal sepsis and to our knowledge neither has been
6
7 61 thoroughly evaluated to assess for impact in increasing awareness.
8
9

10 62 This evaluation looked at recognition and exposure to the GLOSS campaign materials and changes in
11
12 63 provider awareness of maternal sepsis after campaign implementation. The latter included changes
13
14 64 in knowledge on maternal sepsis and perception of enabling environments for identification and
15
16 65 management of maternal sepsis.
17
18
19

20 66 **METHODS**

21
22
23 67 The GLOSS campaign was designed to accompany the Global Maternal Sepsis Study with the goal of
24
25 68 raising awareness on maternal sepsis among healthcare providers working in participating facilities.
26
27 69 Details regarding study protocol, including selection of countries and facilities was published
28
29 70 elsewhere.[12] In short, GLOSS was a facility-based, one-week inception cohort study which enrolled
30
31 71 pregnant or recently pregnant women with suspected or confirmed infection at 713 healthcare
32
33 72 facilities in pre-specified geographical areas located in 52 low-, middle-, and high-income
34
35 73 countries.[12]
36
37
38

39 74 **The STOP SEPSIS! awareness campaign**

40
41
42 75 The campaign launch was planned for before study implementation continuing throughout data
43
44 76 collection and beyond. It was designed using existing frameworks for public information campaigns,
45
46 77 social marketing, health communication, and behaviour change.[13,18–20] The development of the
47
48 78 campaign included an overarching communication strategy using a multi-component approach
49
50 79 delivering a simple and consistent message through visually-attractive media.[21]
51
52
53
54
55
56
57
58
59
60

1
2
3 80 The campaign had a soft launch with an online congress on 12 September 2017 and the full campaign
4
5 81 rollout began on 06 November 2017, which included a website, printed materials, social media
6
7 82 messaging, press releases. While global coordination of the campaign was undertaken by WHO,
8
9 83 implementation of the campaign was the remit of GLOSS country coordinators. **Box 1** describes the
10
11 84 different actions and components that were necessary for the design and development of the *STOP*
12
13 85 *SEPSIS! awareness campaign*.

14
15
16
17 **Box 1. Actions and components for the *STOP SEPSIS! awareness campaign***

- 18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- *Select a campaign lead.* A campaign lead was selected to coordinate and assist with the development of the campaign strategy and execution, and evaluation plan at a global level. This person ensured execution of each of the steps, supported the communication company and the study country coordinators in the participating countries who interacted with the providers working in the participating facilities.
 - *Agree on a budget to fund the campaign.* Funds were necessary to cover the costs of the campaign lead, the communication company, and support to countries for printing of materials. The cost of this campaign was USD 200,000.
 - *Seek the assistance of health and media communication experts.* A communication company with expertise in global health was contracted to lead the design and development of the GLOSS campaign concept and look.
 - *Decide on the minimum set of materials and activities to be developed and implemented.* With input from people in the field who would be targeted through the campaign, the decision to have posters, infographics, press release and other presentation templates, social media messaging, and a website was agreed upon. In addition, a global congress was conceived in collaboration with partners from the Global Sepsis Alliance.
 - *Develop campaign messaging, image, and logo.* A main message, tagline, and logo were designed with assistance from the communication company, content experts in maternal sepsis, and country/regional coordinators for GLOSS.
 - *Develop an evaluation plan.* Given the breadth and geographical extent of the campaign's target population an online survey was used to collect providers' knowledge, attitudes, practices at baseline and post-campaign, including additional measures of campaign recognition and exposure at post-campaign. Paper-based surveys were used on demand.
 - *Support the printing and upkeep of materials.* The campaign lead coordinated translation of all materials into five UN official languages and three additional languages as per GLOSS country coordinators' request. Participating countries were provided with funds needed to print the posters and infographics. Campaign lead was also in charge of regular upkeep of the dedicated website which includes timely news stories.
 - *Implement the campaign.* This included:
 - *WSC Spotlight Congress.* A free, online congress focusing specifically on maternal and neonatal sepsis offered in collaboration with the Global Sepsis Alliance (<https://wscspotlight.org/>). The 25 presentations given over four sessions were later made available as YouTube videos and podcasts for free, with subtitles in multiple languages.

- *Website.* A dedicated website used both as a repository of campaign materials for free download and to disseminate news about the study (<http://srhr.org/sepsis>).
- *Print materials.* Posters with information about the study and infographics on maternal sepsis prevention, and identification and management to be displayed in different areas where women with suspected or confirmed infection could be found (e.g. labour ward, patient waiting area).
- *Press releases.* Templates for announcing the objectives of the study and the campaign; countries/facilities were encouraged to engage local media for this purpose.
- *Social media.* Campaign messaging disseminated and multiplied using social media through HRP's Twitter platform (@HRPresearch).
- *Expand the effect of the campaign.* Countries were encouraged to take ownership over the campaign and develop additional materials and organise activities prior to the start of study data collection.

86

87 **Evaluation of the STOP SEPSIS! awareness campaign**

88 We used an independent sample pre-post intervention design through online and paper-based
89 surveys. Details regarding the definition used for awareness for this campaign, survey formulation
90 and dissemination, including analysis of baseline data have been published elsewhere.[22] Briefly, a
91 pre-campaign 32-question survey was developed to gather baseline information on healthcare
92 providers' awareness of maternal sepsis through self-reported knowledge on maternal sepsis and
93 perception of their work environments as enabling for the identification and management of
94 maternal sepsis. Knowledge was assessed through questions relating to whether respondents had
95 heard of maternal sepsis, correct identification of criteria that define maternal sepsis (infection plus
96 organ dysfunction), and identification of correct initial management of maternal sepsis and infections
97 (antibiotics and fluids) when maternal sepsis was suspected in the case vignette presented in the
98 survey. Perception of enabling environments was assessed through self-reported confidence in
99 making right decisions, reported availability of resources for correct identification and management,
100 and feeling of support from their work environments in dealing with maternal sepsis, using a five-
101 point Likert-scale. The same survey was administered at post-campaign to assess changes in
102 knowledge and perception of their environments; 14 additional questions were included in the post-

1
2
3 103 survey which considered respondents' recognition of and exposure to the campaign, such as
4
5 104 knowledge about the study and the campaign, message recall, engagement with social media for the
6
7 105 campaign, and whether the campaign materials prompted changes in behaviour. See **Appendix 1** for
8
9 106 a copy of the surveys.

11
12 107 Eligible respondents were healthcare providers working in GLOSS participating facilities in countries
13
14 108 that received financial support for campaign implementation (N=46); we excluded all surveys from
15
16 109 respondents that did not explicitly state that they were providers caring for women with infections
17
18 110 in healthcare facilities (e.g., hospital administrators, physical therapists, or community health
19
20 111 workers, or if the field was left blank) and from countries with less than two responses at either pre-
21
22 112 or post-campaign (N=9). See **Figure 1** for a map of all the countries eligible for this evaluation. The
23
24 113 surveys were distributed using a snowballing technique and were available in eight languages:
25
26 114 Arabic, English, French, Italian, Portuguese, Russian, Spanish, and Vietnamese. The surveys were
27
28 115 available for over 30 days (pre-campaign between 29 September and 05 November 2017, post-
29
30 116 campaign between 31 January and 11 March 2018). Weekly reminders were sent through the online
31
32 117 tool and via email to non-respondents. Targeted outreach was undertaken in countries with fewer
33
34 118 than two responses. The campaign was active between 06 November 2017 and 15 January 2018;
35
36 119 however, countries were encouraged to continue to use the materials beyond GLOSS study
37
38 120 implementation. Ethical approval for GLOSS and the awareness campaign was obtained from WHO's
39
40 121 Ethics Review Committee (protocol ID A65787) and from local and facility ethics committees as
41
42 122 necessary.
43
44
45
46
47

48 123 **Data analysis**

49
50
51 124 We used descriptive analysis to provide frequencies and percentages for the characteristics of the
52
53 125 sample, knowledge and perceived enabling environments, and for all the questions relating to
54
55 126 campaign recognition and exposure. The latter was assessed through post-campaign surveys only
56
57

1
2
3 127 and complemented with self-reported accounts by GLOSS country coordinators. Text-based
4
5 128 responses were codified into numerical values according to common emerging themes. All Likert-
6
7 129 scale answers were dichotomized assigning a 1 to the two most favourable responses (i.e., they felt
8
9 130 *very* or *somewhat* confident about making the right decision) and 0 to the combination of remaining
10
11 131 options (*neutral*, *not very confident* or *not confident at all*). While previously we assessed
12
13 132 dichotomization using 1 to the single most favourable response (i.e., respondent felt *very confident*)
14
15 133 and a 0 to the combination of remaining options (*somewhat confident*, *neutral*, *not very confident* or
16
17 134 *not confident at all*)[22] we decided to include a more flexible definition of confidence, perception of
18
19 135 availability of resources, and feeling of support to allow for a more robust denominator that would
20
21 136 enable comparisons. See **Appendix 2** for results of the overall analysis using this second
22
23 137 dichotomization not used in this evaluation.
24
25
26
27

28 138 To assess impact of the campaign we conducted several analyses. First, we calculated percentage
29
30 139 change $[(\% \text{ in post} - \% \text{ in pre})/\% \text{ in pre}] \times 100$ and estimated odds ratios (ORs) to determine
31
32 140 differences in respondent knowledge and perception of enabling environments after campaign
33
34 141 implementation relative to baseline measure for the total sample and by respondent characteristics.
35
36 142 Due to the methodology used for survey dissemination and anonymity of surveys, this was not a
37
38 143 matched sample, paired response pre-post analysis. Sensitivity analyses were conducted restricting
39
40 144 the population to facilities from which we received at least one survey response and at least two
41
42 145 responses, and to countries with more than 30 responses per country at pre- and at post-campaign
43
44 146 survey.
45
46
47

48 147 Second, we used multivariate logistic regression models to explore the association between
49
50 148 respondents' and facilities' characteristics at pre- and post-campaign and change in components of
51
52 149 awareness after campaign implementation. Based on analysis of baseline data and our assumptions
53
54 150 on characteristics that would be associated with levels of awareness,[22] we included the following
55
56
57
58
59
60

1
2
3 151 variables in the model: whether respondent was a physician, years of work experience, region where
4
5 152 the respondent worked, whether the country had implemented an *expanded* version of the campaign,
6
7 153 and whether the facility was a level III facility. Countries were considered to have implemented an
8
9 154 expanded version of the campaign if they had not only printed and displayed all posters and
10
11 155 infographics, prepared and disseminated press releases, but if they had also organized other
12
13 156 activities or developed other materials for the campaign. Since less than 20% of respondents
14
15 157 participated in the World Sepsis Congress Spotlight we did not include this variable in our models.
16
17 158 We looked at effect modification by examining interactions between the time of the survey (pre- or
18
19 159 post-) and each of the characteristics included in the model.
20
21
22

23 160 We used Pearson's χ^2 test to compare proportions and Wald's test to assess for significant differences
24
25 161 in the models including interaction terms. Logistic regression analysis was used to estimate odds
26
27 162 ratios between pre- and post-, crude and adjusted, clustering at the geographical area level. Statistical
28
29 163 significance is reported at $p < 0.05$. Stata (version 14.2, College Station, TX) was used for the analyses.
30
31
32

33 164 **Patient and public involvement**

34
35
36 165 This research was done without patient or public involvement. While the development of the
37
38 166 campaign was done with input from study regional and country coordinators, respondents to the
39
40 167 surveys were not invited to comment on the study design or to contribute to the writing of this
41
42 168 manuscript given their anonymity.
43
44
45

46 169 **Role of the funding source**

47
48
49 170 The funders of the study had no role in study design, data collection, data analysis, data
50
51 171 interpretation, or writing of this original article.
52
53

54 172 **RESULTS**

1
2
3 173 A total of 2,188 surveys met our inclusion criteria. Of these, 1,155 from 192 facilities were received
4
5 174 at baseline and 1,033 from 196 facilities at post-campaign. There were no significant differences in
6
7 175 sociodemographic characteristics between respondents at pre- and post-campaign surveys, except
8
9 176 for a higher proportion of respondents working in a public facility at post-campaign and the higher
10
11 177 proportion of respondents from countries where an expanded version of the campaign was
12
13 178 implemented (**Table 1**). Responses came from the same overall countries at pre- and post-campaign.
14
15 179 Because of the technique used for survey dissemination and because we did not know the total
16
17 180 population of potentially exposed healthcare providers working in GLOSS participating facilities
18
19 181 (provider turnover, rotation, and replacements is high), we were unable to calculate a response rate.
20
21 182 However, since the campaign was implemented equally at the geographical area level, if providers
22
23 183 remained within the study area they would have been exposed to the campaign. Results from the
24
25 184 sensitivity analyses showed that overall findings in the sub-groups considered were consistent with
26
27 185 the results from the complete sample (**Appendix 3**); for this reason, we used the entire sample for
28
29 186 all subsequent analyses.
30
31
32
33

34 **Table 1. Characteristics of respondents and the facilities in which they work at pre- and**
35 **post-campaign survey (N=2,188)**

<i>Respondent characteristics</i>	Pre-campaign (N=1,155)		Post-campaign (N= 1,033)	
	N	%	N	%
<i>Age (in years)</i>	1,147		1,020	
<31	354	31	301	30
31-40	389	34	407	40
>40	404	35	312	31
<i>Sex</i>	1,153		1,022	
Male	287	25	223	22
Female	866	75	799	78
<i>Qualification</i>	1,151		1,025	
Nurse/auxiliary nurse/midwife	440	38	456	44
Physician	561	49	456	44
Resident	150	13	113	11
<i>Years of work experience</i>	1,107		970	
<10	541	49	476	49
10-20	349	32	320	33

	>20	217	20	174	18
<i>Region</i>		1,155		1,033	
	Africa	224	19	226	22
	Asia	173	15	170	16
	Eastern Mediterranean	171	15	165	16
	Europe [‡]	137	12	97	9
	Latin America	450	39	375	36
<i>Level of the facility in which respondent works</i>		1,153		1,033	
	I	127	11	166	16
	II	236	20	258	25
	III	790	69	609	59
<i>Respondent worked in a public facility*</i>		1,154		1,033	
	Yes	937	81	928	90
	No	217	19	105	10
<i>Country implemented an expanded version of campaign*</i>		1,155		1,033	
	Yes	705	39	533	52
	No	450	61	500	48

[‡]Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan), in line with WHO regions

* $p < 0.05$

187

188 We first present the results relating to campaign recognition and exposure and then results relating
189 to changes in knowledge and perception of respondents' work environments.

190 **Campaign recognition and exposure**

191 Campaign recognition and exposure were high among most of the post-campaign survey respondents.
192 Seventy-six percent of respondents stated they noticed the materials in their facilities; among those,
193 94% reported finding the materials helpful, 90% that the materials helped increase awareness on
194 maternal sepsis and 88% that the materials motivated them to do something differently. Only 8% of
195 respondents had used Twitter to amplify the message of the campaign (**Figure 2**). Among
196 respondents that stated that the information provided in the materials motivated them to do
197 something differently than before, 83% stated that it motivated them to suspect maternal sepsis and

1
2
3 198 77% to act fast. (**Figure 3**). Among respondents stating that the materials had not motivated them to
4
5 199 do anything differently, 45% said it was because they already knew about maternal sepsis
6
7 200 identification and management while 12% stated they had not seen the campaign materials.
8
9
10 201 Country coordinators shared anecdotal experiences of increased awareness in their facilities and the
11
12 202 implementation of changes in practice and policies because of the study and the campaign. These
13
14 203 accounts speak of a broader engagement with maternal sepsis identification and management. See
15
16
17 204 **Box 2** for some examples.
18
19

20 **Box 2. Accounts from the field***

21
22
23 *Implementation of the campaign changed the way the city's providers acted. First, it helped in*
24 *bridging the gap between academics and providers, which, in turn, helped motivate the entire staff*
25 *around the study. The campaign helped us all feel more committed with the study. And, most*
26 *importantly, it helped shed light on a problem (maternal sepsis) that we hadn't made public before.*
27 *(Cali, Colombia)*

28
29 *In (our) facility there was already a protocol for sepsis early recognition, but the campaign, as well*
30 *as the study made it come alive again. Sepsis was on everyone's eyes and mouths. The teams were very*
31 *permeable to knowledge and eager to recognize and treat sepsis immediately. (Campinas, Brazil)*

32
33 *Participation in the campaign allowed me to see that we can find cases of maternal sepsis in the most*
34 *diverse locations in a facility. And that invariably the most complex cases were those resulting from*
35 *a condition that was neglected or treated incorrectly/untimely. (Maputo, Mozambique)*

36
37 *Despite having some protocols in place, during the campaign and study we realized that these were*
38 *not sufficient to detect women with infection. This campaign was very important and helped us find*
39 *a lot of cases that might have been missed otherwise (...) We are planning on improving reporting*
40 *mechanisms of any suspected cases and supportive supervision and surveillance as a result of this*
41 *study. (Ulaanbaatar, Mongolia)*

42
43
44 *As a result of our participation in GLOSS, we actually committed as a Program in our 2017 Maternal*
45 *Death Review Forum to eliminate maternal sepsis as a cause of maternal death. (Manila, Philippines)*

46
47 *(Since implementing the GLOSS awareness campaign at a national level, we noticed that) we have*
48 *prioritized the identification and suspicion of maternal and neonatal sepsis in all level I facilities, in*
49 *specialized hospital care, and in the public health agenda. (Mexico City, Mexico)*

50
51 * These reports first appeared in a blog post on the Merck for Mothers website in April 2018:
52 <https://www.msdformothers.com/blog/assessing-addressing-maternal-sepsis.html> and in a news story on
53 WHO/HRP's website in September 2018: [https://www.who.int/reproductivehealth/maternal-sepsis-](https://www.who.int/reproductivehealth/maternal-sepsis-mexico/en/)
54 [mexico/en/](https://www.who.int/reproductivehealth/maternal-sepsis-mexico/en/)
55

56 205
57
58
59
60

206 Knowledge on maternal sepsis and perception of enabling environments

207 At pre-campaign survey, 92% of respondents (1,049/1,144) had heard of maternal sepsis. However,
 208 only 16% (109/673) of respondents were able to correctly identify the definition criteria of maternal
 209 sepsis and 45% (114/251) identified the correct management for maternal sepsis. In addition, at pre-
 210 campaign, most survey respondents stated that their work environments were enabling for maternal
 211 sepsis identification and management: 78% (897/1,155) stated that they felt confident of making
 212 right decisions, 79% (909/1,155) that they perceived resources were available, and 80%
 213 (921/1,155) that they felt supported by their facilities. See **Table 2** for overall results.

214 After campaign implementation there was a significant decrease in respondents who stated not
 215 having heard of maternal sepsis (-63.4% change; OR 0.35, 95% CI 0.18-0.68). There was also a
 216 significant increase in perceived confidence in making right decisions with regards to maternal sepsis
 217 identification and management (7.3% change; OR 1.44, 95% CI 1.01-2.06), although this level was
 218 quite high at pre-campaign (78%). There was a slight increase in respondents' ability to identify the
 219 correct management when maternal sepsis was suspected after the implementation of the campaign,
 220 but this was not statistically significant (30.8% change; OR 1.76, 95% CI 0.73-4.21). See **Appendix**
 221 **4a and 4b** for these results according to respondent and facility characteristics.

Table 2. Respondent knowledge on maternal sepsis and perception of enabling environments for maternal sepsis identification and management at pre- and post-campaign and changes after campaign implementation (N=2,188)

	Pre-campaign n/N (%)	Post-campaign n/N (%)	Pre-post cOR [‡] [95% CI] [¶]	Percentage change %
<i>Knowledge on maternal sepsis</i>				
Had not heard of maternal sepsis ^(A)	95/1,144 (8.3)	31/1,021 (3.0)	0.35* [0.18-0.68]	-63.4
Correctly identified the two criteria to define maternal sepsis ^(B)	109/673 (16.2)	74/647 (11.4)	0.67 [0.43-1.17]	-29.4
Correctly identified management of sepsis when maternal sepsis was suspected ^(C)	114/251 (45.4)	142/239 (59.4)	1.76 [0.73-4.21]	30.8

Perception of enabling environment for maternal sepsis identification and management

Confident of making right decisions	897/1,155 (77.7)	861/1,033 (83.4)	1.44* [1.01-2.06]	7.3
Resources available to make right decisions	909/1,155 (78.7)	814/1,033 (78.8)	1.01 [0.68-1.49]	0.1
Supported by facility in making right decisions	921/1,155 (79.7)	840/1,033 (81.3)	1.11 [0.80-1.54]	2.0

cOR: crude odds ratio; CI: confidence interval

Percentage change: [(% in post - % in pre)/% in pre]x100

‡Refers to odds ratio between pre- and post-campaign; OR calculated clustering at the geographical area level

*‡reference group: pre-campaign; *p<0.05*

^(A) Responded NO to the question "have you ever heard of the term maternal sepsis?"

^(B) Answered INFECTION and ORGAN DYSFUNCTION to the question: "what two criteria best describe maternal sepsis?"

^(C) Answered FLUIDS and ANTIBIOTICS to the question: "what would be the first two things a woman should receive," when the respondent answered INFECTION/SEPSIS to the question: "what would you first think could be causing her to feel this way?"

222

223 After controlling for respondent and facility characteristics, being a physician, having less than 10

224 years of experience, and working in a level III facility were associated with decreased odds of not

225 having heard of maternal sepsis at pre-campaign (**Table 3**). Respondents from facilities that had

226 implemented an expanded version of the campaign were more likely to have heard of maternal sepsis

227 and identify the correct management of maternal sepsis at post-campaign. Respondents with less

228 than 10 years of experience were more likely to have heard of maternal sepsis at pre-campaign, but

229 there were no differences across providers with different years of experience after the campaign.

230 Physicians were more likely to respond that they felt confident in making the right decisions at post-

231 campaign, while being a physician and having more than 20 years of experience had a significant

232 interaction with time of the survey with regards to perception of availability of resources and support

233 from their facilities. At pre- and post-campaign, respondents with 20 years or more of experience

234 were more likely to perceive availability of resources for making right decisions and to feel supported

235 by their facilities and these differences between groups were significant after the campaign (**Table**

1
2
3 236 4). No differences in the perception of enabling environments were seen among respondents from
4
5 237 facilities that had implemented an expanded version of the campaign.
6
7

8 238
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2

3 **Table 3. Knowledge on maternal sepsis adjusted for respondents' characteristics (N=2,188)**

	Had not heard about maternal sepsis					Correctly identified the two criteria to define maternal sepsis					Correctly identified management of sepsis when maternal sepsis was suspected				
	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test
Respondent characteristics	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>
Physician	0.29*	0.10-0.85	0.58	0.17-1.93	0.108	1.78	0.80-3.95	3.85*	1.54-9.60	0.175	2.07*	1.24-3.45	2.81*	1.08-7.30	0.583
Years of work experience															
<10	0.50*	0.26-0.96	1.57	0.77-3.18	0.035	1.08	0.60-1.96	0.86	0.55-1.34	0.352	0.86	0.53-1.40	0.61	0.30-1.23	0.775
10-20	1 (ref)		1 (ref)			1 (ref)		1 (ref)			1 (ref)		1 (ref)		
>20	1.21	0.61-2.38	0.73	0.19-2.87		1.17	0.59-2.30	1.50*	1.02-2.21		1.59	0.60-4.22	0.9	0.30-2.71	
Country implemented an expanded version of campaign	1.54	0.46-5.12	0.21*	0.06-0.78	0.004	1.18	0.53-2.65	0.86	0.31-2.34	0.281	2.78*	1.01-7.59	8.02*	2.03-31.73	0.437
Respondent worked in a level III facility	0.45*	0.21-0.96	1.79	0.59-5.42	0.006	1.63	0.77-3.45	2.80*	1.32-5.94	0.314	2.10	0.85-5.16	1.14	0.43-3.02	0.406

23[†]Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan), in line with WHO regions

24[‡]Countries were considered to have implemented an expanded version of the campaign if they had not only printed and displayed all posters and infographics, prepared and disseminated press releases, but if they had also organized other activities or developed other materials for the campaign.

26[§]Adjusting for whether respondent was a physician, years of work experience, region, whether the country implemented an expanded version of the campaign, and whether respondent worked in a level III facility, clustering at the geographical area level

28^{||}aOR: adjusted odds ratio; CI: confidence interval; Wald's test used to assess for differences in the models including interaction terms; **p*<0.05

30 239

31
32 240

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 4. Perception of enabling environments for maternal sepsis identification and management adjusted for respondents' characteristics (N=2,188)

Respondent characteristics	Confident of making right decisions					Resources available to make right decisions					Supported by facility in making right decision				
	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test	Pre-campaign		Post-campaign		Wald's test
	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>	aOR	95% CI	aOR	95% CI	<i>p</i>
<i>Physician</i>	1.02	0.64-1.64	1.69*	1.19-2.40	0.246	0.81	0.55-1.20	1.39	0.99-1.95	0.021	0.78	0.55-1.09	1.26	0.83-1.92	0.017
<i>Years of work experience</i>															
<10	0.74	0.51-1.09	0.88	0.63-1.22	0.025	0.63*	0.41-0.97	0.82	0.53-1.27	0.014	0.70	0.46-1.06	0.95	0.69-1.30	0.038
10-20	1 (ref)		1 (ref)			1 (ref)		1 (ref)			1 (ref)		1 (ref)		
>20	1.20	0.76-1.91	2.54*	1.38-4.64		1.66*	1.08-2.54	2.48*	1.49-4.13		1.60*	1.07-2.40	2.78*	1.84-4.20	
<i>Country implemented an expanded version of campaign</i>	0.65	0.36-1.16	0.91	0.56-1.48	0.605	1.00	0.52-1.94	1.57	0.85-2.88	0.241	1.32	0.86-2.03	1.37	0.90-2.07	0.092
<i>Respondent worked in a level III facility</i>	0.90	0.55-1.47	0.64*	0.41-1.00	0.581	1.39	0.86-2.23	1.27	0.79-2.04	0.255	0.88	0.53-1.46	1.18	0.67-2.07	0.116

*Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan), in line with WHO regions

Countries were considered to have implemented an expanded version of the campaign if they had not only printed and displayed all posters and infographics, prepared and disseminated press releases, but if they had also organized other activities or developed other materials for the campaign.

Adjusting for whether respondent was a physician, years of work experience, region, whether the country implemented an expanded version of the campaign, and whether respondent worked in a level III facility, clustering at the geographical area level

aOR: adjusted odds ratio; CI: confidence interval; Wald's test used to assess for differences in the models including interaction terms; **p*<0.05

241

1
2
3 242 **DISCUSSION**
4
5

6 243 To the best of our knowledge, this is the first study to assess impact of an awareness campaign aimed
7
8 244 at healthcare providers and implemented at a global level where pre-campaign and post-campaign
9
10 245 data were collected in addition to measures relating to campaign recognition and exposure. Most
11
12 246 healthcare providers stated that the campaign helped increase awareness of maternal sepsis and
13
14 247 motivated them to do something differently, particularly to suspect maternal sepsis and act faster.
15
16 248 Reports from the field also support this finding that exposure to the campaign increased sensitization
17
18 249 to maternal infections and sepsis. Moreover, most survey respondents had heard of maternal sepsis
19
20 250 even before campaign implementation; after the campaign this increased significantly. Although
21
22 251 most respondents perceived their enabling environments in a positive way before campaign
23
24 252 implementation, there was an increase in respondent confidence to make the right decisions
25
26 253 regarding maternal sepsis identification and management after campaign implementation.
27
28
29
30

31 254 The *STOP SEPSIS! awareness campaign* implementation was effective with regards to respondents'
32
33 255 recognition of and exposure to the campaign; other campaign evaluations have used these measures
34
35 256 to positively assess short-term impact of campaigns.[23–25] Furthermore, consistent and repeat
36
37 257 exposure to campaign messaging have shown to increase awareness;[13] while exposure was only
38
39 258 measured over the course of this evaluation period corresponding to the intended implementation
40
41 259 period of the campaign, the fact that most respondents stated the campaign raised awareness is a
42
43 260 promising trend in the right direction.
44
45
46

47 261 Overall knowledge about maternal sepsis increased from pre- to post-campaign implementation
48
49 262 among respondents to our survey with regards to having heard about maternal sepsis. Our finding
50
51 263 that overall knowledge increased is supported by existing literature that suggests that campaigns can
52
53 264 increase knowledge on a specific topic among healthcare providers[14,26,27] as well as among the
54
55 265 general population.[23,28,29] The fact that there was a slight increase in identifying the correct
56
57
58
59
60

1
2
3 266 management of maternal sepsis is important. Research has shown that knowing what is needed to
4
5 267 manage maternal sepsis correctly and early management of maternal sepsis are critical to
6
7 268 implementing any changes in providers' behaviour and improving maternal health
8
9 269 outcomes.[6,30,31] The low number of providers able to identify the two criteria defining maternal
10
11 270 sepsis might be more a reflection of the lack of consensus on this condition prior to 2017, rather than
12
13 271 a shortcoming of the campaign.[32] The GLOSS awareness campaign was associated with reducing
14
15 272 differences among groups of healthcare providers depending on their qualifications or years of
16
17 273 experience. This speaks to the importance of including healthcare providers with different
18
19 274 qualifications and years of experience in awareness-raising efforts.

22
23 275 We found there were overall increases in respondent confidence in making right decisions about
24
25 276 maternal sepsis identification and management, but no significant changes with regards to overall
26
27 277 respondent perception of availability of necessary resources and feeling supported by their facilities.
28
29 278 Evidence shows that confidence can not only affect clinical performance;[33] but also that high levels
30
31 279 of confidence among healthcare providers can have a positive impact on patients' perception of
32
33 280 experience of care.[34] However, the change in perception of availability of resources and support
34
35 281 limited to physicians and more experienced providers raises a broader question on actions that
36
37 282 facilities need to take to empower all healthcare workers in feeling that they have the necessary
38
39 283 resources and feel supported to provide quality care. This is especially important if we consider that
40
41 284 a more restrictive definition of enabling environments results in much lower overall levels of
42
43 285 perceived confidence, perception of availability of resources, and feeling of support. Perceived lack
44
45 286 of availability of resources may also be a product of increased awareness of what is necessary to
46
47 287 address maternal sepsis. These findings are a call to hospital administrators and policy-makers to
48
49 288 foster enabling environments and secure availability and access to life-saving resources.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 289 Sepsis awareness is gaining traction on global agendas;[4,10,16] this is supported by evidence from
4
5 290 two studies looking at internet searches on sepsis,[35,36] meaning increases resulting from this
6
7 291 campaign could be responding to natural trends or other factors. It is also possible that awareness
8
9 292 was raised by having participated in the research study and not necessarily because of the campaign;
10
11 293 disentangling the effect of the campaign from that of the implementation of the research study was
12
13 294 impossible. Understanding whether any of these changes are sustained over time would provide us
14
15 295 with further information on the lasting effects of the campaign.

16
17
18
19 296 Literature shows that while a campaign can help in raising awareness, it is insufficient in allowing for
20
21 297 changes in behaviour.[13,19] While behaviour change is important in impacting population-level
22
23 298 health, it is one of many components needed to make significant improvements; evidence from this
24
25 299 study, similar to others, highlight the need for health systems improvements such as availability of
26
27 300 critical resources and support to improve maternal outcomes.[37] Assessing the impact that
28
29 301 increased awareness resulting from a campaign has on behaviour change would provide us with
30
31 302 supporting evidence that campaigns can help in improving health outcomes.

32
33
34
35 303 This study has some limitations. First, we used a pre-post design methodology with no control group
36
37 304 which does not allow to discern the impact of the campaign alone. Second, the method used to
38
39 305 disseminate the survey and the fact that surveys were anonymous made it impossible to match
40
41 306 responses at pre- and post-campaign. Surveys were anonymous to encourage providers to respond
42
43 307 and remove potential response bias. However, it is to note that characteristics of participants at pre-
44
45 308 and post-campaign were similar. Third, because implementation of the campaign was left up to
46
47 309 country coordinators, campaign fidelity was only assessed through healthcare provider self-report
48
49 310 at post-campaign surveys. Fourth, this evaluation was restricted to the duration of the study follow-
50
51 311 up period, hence providing insight into early findings only and limiting our knowledge of lasting
52
53 312 impact of the campaign, which was beyond the goal of this activity. However, our findings suggest

1
2
3 313 that campaigns can have at least short-term effects on provider's knowledge and confidence. The
4
5 314 positive perception of the campaign materials is encouraging. And fifth, since baseline data was
6
7 315 collected after the soft launch of the campaign, the effect of the campaign may have been minimized
8
9 316 because awareness had already been increased through exposure to the online congress as well as
10
11 317 other global activities on sepsis conducted by other groups. However, we know that less than 20% of
12
13 318 respondents participated in the congress.

14
15
16
17 319 Our findings have implications for both practice and research. On the one hand, there appear to be
18
19 320 benefits to coupling large multi-country studies with awareness campaigns. A campaign targeting
20
21 321 healthcare providers can promote their engagement with research studies being conducted,
22
23 322 potentially improving study outcomes. There is also evidence that including an awareness campaign
24
25 323 creates an environment prime to implementing changes to clinical practice as per research study
26
27 324 protocol. On the other hand, there is a clear need for additional research to identify lasting effects of
28
29 325 awareness campaigns, especially as global initiatives focus on increasing awareness on maternal
30
31 326 health issues.

32
33
34
35 327 A campaign designed to raise awareness among healthcare providers working in facilities
36
37 328 participating in a global research study was associated with an increase in having heard of maternal
38
39 329 sepsis, as well as increased provider perception of confidence in making correct decisions. Offering
40
41 330 healthcare providers with the information to make accurate and timely decisions while promoting
42
43 331 environments that enable self-confidence and support could improve maternal sepsis identification
44
45 332 and management, which can ultimately have an impact on maternal health outcomes.

46
47
48
49 333

50 51 52 334 **FIGURES**

53
54
55 335 **Figure 1.** Countries eligible for the GLOSS '*STOP SEPSIS!*' awareness campaign evaluation (N=46)

1
2
3 336 **Figure 2.** Measures of campaign exposure in percentages (N=1,033)
4
5

6 337 **Figure 3.** Responses when answering YES to the question “Did the information provided in the
7
8 338 materials motivate you to do something differently than before?” (N=668). (Respondents were able
9
10 339 to check as many response options as needed)
11
12

13 14 340 **APPENDICES**

15
16
17 341 **Appendix 1.** Global Maternal Sepsis Study – Pre- and Post- Campaign Surveys
18
19

20 342 **Appendix 2.** Respondent perception of enabling environments for maternal sepsis identification and
21
22 343 management at pre- and post-campaign and changes after campaign implementation, limiting to
23
24 344 most favourable responses (N=2,188)
25
26

27 345 **Appendix 3.** Changes in respondent knowledge and perception of enabling environments after
28
29 346 campaign implementation among different sub-groups
30
31

32 347 **Appendix 4.** Changes in respondent knowledge and perception of enabling environments after
33
34 348 campaign implementation according to respondent and facility characteristics
35
36
37

38 349
39
40 350 **Acknowledgments:** The authors wish to thank Khalid Yunis for his contributions to the development
41
42 351 of the campaign, Soe Soe Thwin and Cristina Cuesta for their assistance in the planning and review
43
44 352 of statistical analyses, and all the respondents to the online and paper-based survey. The authors
45
46 353 would also like to acknowledge the contribution and lifelong achievements of co-author Bukola
47
48 354 Fawole, who passed away prior to the publication of this article.
49
50

51 355
52
53
54
55
56
57
58
59
60

1
2
3 356 **Contributors:** The evaluation plan and first draft of this original article was conceived by VB. MB
4
5 357 provided substantial contributions to the data planning and analysis and first versions of this
6
7 358 manuscript. The idea for the inclusion of an awareness campaign was first conceived by JPS. CLTR,
8
9 359 JPS, and EA provided additional feedback on first draft and data analysis. VB, MB, JPS, EA, AB, AOF,
10
11 360 MK, PL, MM, AN, NBO, ZQ were instrumental to campaign design and implementation in their
12
13 361 regions/countries and provided input to data collection tools used for this evaluation. All authors
14
15 362 read and approved the final version. The WHO GLOSS Research Group contributed to different
16
17 363 aspects of the study, from protocol development to acquisition of data and coordination of study in
18
19 364 their countries. VB, MB, and CLTR had full access to all the data and VB has final responsibility for the
20
21 365 decision to submit for publication.
22
23
24
25
26
27
28

29 368 **Funding:** This work was supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special
30
31 369 Programme of Research, Development and Research Training in Human Reproduction (HRP),
32
33 370 Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva,
34
35 371 Switzerland (project A65787), Merck Sharp & Dohme Corp., a wholly owned subsidiary of Merck and
36
37 372 Co., Inc. (Kenilworth, NJ USA), through its Merck for Mothers program, and the United States Agency
38
39 373 for International Development (USAID) Grant number GHA-G-00-09-00003. The views of the funding
40
41 374 bodies have not influenced the content of this manuscript.
42
43
44
45
46

47 376 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
48
49 377 www.icmje.org/coi_disclosure.pdf and declare: support from WHO/SHR, Merck for Mothers, and
50
51 378 USAID for the submitted work; VB, MB, and JPS were employed by WHO at the time of the study; no
52
53 379 other relationships or activities that could appear to have influenced the submitted work.
54
55
56
57
58
59
60

1
2
3 381 **Ethical approval:** Ethical approval for the entire study, including the awareness campaign, was
4
5 382 obtained from WHO's Ethics Review Committee in Geneva, Switzerland (protocol ID A65787) for a
6
7 383 multi-site, multi-country project. A legend was included in the survey stating that response to the
8
9 384 survey implied consent to participate; respondents could recuse themselves at any point during the
10
11 385 survey, including skipping and not answering certain questions.
12
13

14 386

15
16
17 387 **Data sharing:** All enquiries regarding the data and analyses can be made to the corresponding
18
19 388 author.
20
21

22 389 **Transparency:** The lead author (VB) affirms that the manuscript is an honest, accurate, and
23
24 390 transparent account of the study being reported; that no important aspects of the study have been
25
26 391 omitted; and that any discrepancies from the study as planned have been explained.
27
28

29 392

30
31 393 **Disclosure:** This article represents the views of the named authors only and does not represent the
32
33 394 views of the World Health Organization
34
35

36
37 395 **World Health Organization Global Maternal Sepsis Study Research Group (in alphabetical**
38
39 396 **order)**
40

41 397 AFGHANISTAN: Mohammad Iqbal Aman, Bashir Noormal. ARGENTINA: Virginia Díaz, Marisa
42
43 398 Espinoza, Julia Pasquale. BELGIUM: Charlotte Leroy, Kristien Roelens, Griet Vandenberghe. BENIN:
44
45 399 M. Christian Urlyss Agossou, Sourou Goufodji Keke, Christiane Tshabu Aguemon. BOLIVIA: Patricia
46
47 400 Soledad Apaza Peralta, Víctor Conde Altamirano, Rosalinda Hernández Muñoz. BRAZIL: José
48
49 401 Guilherme Cecatti, Carolina C Ribeiro do Valle. BURKINA FASO: Vincent Batiene, Kadari Cisse, Henri
50
51 402 Gautier Ouedraogo. CAMBODIA: Cheang Kannitha, Lam Phirun, Tung Rathavy. CAMEROON: Elie
52
53 403 Simo, Pierre-Marie Tebeu, Emah Irene Yakana. COLOMBIA: Javier Carvajal, María Fernanda Escobar,
54
55
56
57
58
59
60

- 1
2
3 404 Paula Fernández. DENMARK: Lotte Berdiin Colmorn, Jens Langhoff-Roos. ECUADOR: Wilson Mereci,
4
5 405 Paola Vélez. EGYPT: Yasser Salah Eldin, Alaa Sultan. ETHIOPIA: Abdulfetah Abdulkadir Abdosh, Alula
6
7 406 M. Teklu, Dawit Worku Kassa. GHANA: Richard Adanu, Philip Govule, Charles Noora Lwanga.
8
9 407 GUATEMALA: William Enrique Arriaga Romero, María Guadalupe Flores Aceituno. HONDURAS:
10
11 408 Carolina Bustillo, Rigoberto Castro, Bredy Lara. INDIA: Vijay Kumar, Vanita Suri, Sonia Trikha. ITALY:
12
13 409 Irene Cetin, Serena Donati, Carlo Personeni. KAZAKHSTAN: Guldana Baimussanova, Saule Kabylova,
14
15 410 Balgyn Sagyndykova. KENYA: George Gwako, Alfred Osoi, Zahida Qureshi. KYRGYZSTAN: Raisa
16
17 411 Asylbasheva, Aigul Boobekova, Damira Seksenbaeva. LEBANON: Faysal El Kak, Saad Eddine Itani,
18
19 412 Sabina Abou Malham. LITHUANIA: Meilė Minkauskienė, Diana Ramašauskaitė. MALAWI: Owen
20
21 413 Chikhwaza, Luis Gadama, Eddie Malunga. MALI: Haoua Dembele, Hamadoun Sangho, Fanta Eliane
22
23 414 Zerbo. MEXICO: Filiberto Dávila Serapio, Nazarea Herrera Maldonado, Juan Ismael Islas Castañeda.
24
25 415 REPUBLIC OF MOLDOVA: Tatiana Cauaus, Ala Curteanu, Victor Petrov. MONGOLIA: Yadamsuren
26
27 416 Buyanjargal, Seded Khishgee, Bat-Erdene Lkhagvasuren. MOROCCO: Bouchra Assarag, Amina
28
29 417 Essolbi, Rachid Moulki. MOZAMBIQUE: Zara Jaze, Arlete Mariano, Nafissa Bique Osman. MYANMAR:
30
31 418 Hla Mya Thway Einda, Thae Maung Maung, Khaing Nwe Tin. NEPAL: Tara Gurung, Amir Babu
32
33 419 Shrestha, Sangeeta Shrestha. NETHERLANDS: Kitty Bloemenkamp, Marcus J. Rijken, Thomas Van Den
34
35 420 Akker. NICARAGUA: María Esther Estrada, Néstor J. Pavón Gómez. NIGERIA: Olubukola Adesina,
36
37 421 Chris Aimakhu, Bukola Fawole. PAKISTAN: Rizwana Chaudhri, Saima Hamid, M. Adnan Khan. PERU:
38
39 422 María del Pilar Huatuco Hernández, Nelly M. Zavaleta Pimentel. PHILIPPINES: Maria Lu Andal,
40
41 423 Carolina Paula Martin, Zenaida Dy Recidoro. ROMANIA: Mihaela Budianu, Lucian Pușcașiu. SENEGAL:
42
43 424 Léopold Diouf, Dembo Guirassy, Philippe Marc Moreira. SLOVAKIA: Miroslav Borovsky, Ladislav
44
45 425 Kovac, Alexandra Kristufkova. SOUTH AFRICA: Sylvia Cebekhulu, Laura Cornelissen, Priya Soma-
46
47 426 Pillay. SPAIN: Vicenç Cararach, Marta López, María José Vidal Benedé. SRI LANKA: Hemali Jayakody,
48
49 427 Kapila Jayaratne, Dhammica Rowel. SUDAN: Mohamed Elsheikh, Wisal Nabag, Sara Omer.
50
51 428 TAJIKISTAN: Victoria Tsoy, Urunbish Uzakova, Dilrabo Yunusova. THAILAND: Thitiporn
52
53
54
55
56
57
58
59
60

1
2
3 429 Siriwachirachai, Thumwadee Tangsiriwatthana. UNITED KINGDOM: Catherine Dunlop, Marian
4
5 430 Knight, David Lissauer. URUGUAY: Aquilino M. Pérez, Jhon Roman, Gerardo Viturera. VIET NAM:
6
7 431 Dinh Anh Tuan, Luong Ngoc Truong, Nghiem Thi Xuan Hanh. ZIMBABWE: Mugove Madziyire, Thulani
8
9 432 Magwali, Stephen Munjanja. Regional Coordinators: Edgardo Abalos, Adama Baguiya, Mónica
10
11 433 Chamillard, Bukola Fawole, Marian Knight, Seni Kouanda, Pisake Lumbiganon, Ashraf Nabhan, Ruta
12
13 434 Nadisaukiene. Technical Advisory Group: Linda Bartlett, Fernando Bellissimo-Rodrigues, Shevin T.
14
15 435 Jacob, Sadia Shakoor, Khalid Yunis. Data management and analysis: Liana Campodónico, Cristina
16
17 436 Cuesta, Hugo Gamero, Daniel Giordano. WHO coordinating Unit: Fernando Althabe, Mercedes Bonet,
18
19 437 Vanessa Brizuela, A. Metin Gülmezoglu, João Paulo Souza.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 Reinhart K, Daniels R, Kissoon N, *et al*. Recognizing Sepsis as a Global Health Priority —
2 A WHO Resolution. *N Engl J Med* 2017;**377**:414–7. doi:10.1056/NEJMp1707170
- 3
4
5
6 438 1
7 439
- 8
9 440 2
10 441
11
12
13 442 3
14 443
15 444
16
17 445 4
18 446
19 447
20 447
21
22 448 5
23 449
24
25 450 6
26 451
27 451
28 452
29
30 453 7
31 454
32
33 455 8
34 456
35
36 457 9
37 458
38 458
39 459
40
41 460 10
42 461
43
44 462 11
45 463
46 463
47 464
48
49 465 12
50 466
51 467
52
53 468 13
54 469
55 469
56
57
58
59
60

- 1
2
3 470 14 Pittet D, Hugonnet S, Harbarth S, *et al.* Effectiveness of a hospital-wide programme to
4 471 improve compliance with hand hygiene. *The Lancet* 2000;**356**:1307–12.
5 472 doi:10.1016/S0140-6736(00)02814-2
6
7
8 473 15 Glanz K, Rimer BK, Lewis, editors. *Health Behavior and Health Education: Theory,*
9 474 *Research, and Practice.* 3rd ed. San Francisco: : Jossey-Bass 2002.
10
11 475 16 Global Sepsis Alliance. <https://www.global-sepsis-alliance.org/> (accessed 27 Feb
12 476 2019).
13
14 477 17 UK Sepsis Trust. Sepsis Trust. <https://sepsistrust.org/> (accessed 27 Feb 2019).
15
16 478 18 Weiss JA, Tschirhart M. Public Information Campaigns as Policy Instruments. *J Policy*
17 479 *Anal Manage* 1994;**13**:82. doi:10.2307/3325092
19
20 480 19 Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health
21 481 behaviour. *The Lancet* 2010;**376**:1261–71. doi:10.1016/S0140-6736(10)60809-4
22
23 482 20 *Making Health Communication Programs Work.* National Cancer Institute 2004.
24 483 <https://www.cancer.gov/publications/health-communication/pink-book.pdf> (accessed
25 484 11 Jan 2017).
26
27
28 485 21 O'Connor M, McGowan K, Jolivet RR. An awareness-raising framework for global health
29 486 networks: lessons learned from a qualitative case study in respectful maternity care.
30 487 *Reprod Health* 2019;**16**. doi:10.1186/s12978-018-0662-9
31
32 488 22 Brizuela V, Bonet M, Souza JP, *et al.* Factors influencing awareness of healthcare
33 489 providers on maternal sepsis: a mixed-methods approach. *BMC Public Health*
34 490 2019;**19**:683. doi:10.1186/s12889-019-6920-0
35
36
37 491 23 Kaufman MR, Harman JJ, Smelyanskaya M, *et al.* "Love me, parents!": impact evaluation
38 492 of a national social and behavioral change communication campaign on maternal health
39 493 outcomes in Tanzania. *BMC Pregnancy Childbirth* 2017;**17**:305. doi:10.1186/s12884-
40 494 017-1470-x
41
42
43 495 24 Evans WD, Uhrig J, Davis K, *et al.* Efficacy methods to evaluate health communication
44 496 and marketing campaigns. *J Health Commun* 2009;**14**:315–30.
45 497 doi:10.1080/10810730902872234
46
47 498 25 Bazzo S, Black D, Mitchell K, *et al.* 'Too Young To Drink'. An international
48 499 communication campaign to raise public awareness of fetal alcohol spectrum disorders.
49 500 *Public Health* 2017;**142**:111–5. doi:10.1016/j.puhe.2016.08.001
51
52 501 26 Al-Dorzi HM, Cherfan A, Al-Harbi S, *et al.* Knowledge of thromboprophylaxis guidelines
53 502 pre- and post-didactic lectures during a venous thromboembolism awareness day at a
54 503 tertiary-care hospital. *Ann Thorac Med* 2013;**8**:165–9. doi:10.4103/1817-1737.114298
55
56
57
58
59
60

- 1
2
3 504 27 Pattinson RC, Bergh A-M, Makin J, *et al.* Obstetrics knowledge and skills training as a
4 505 catalyst for change. *S Afr Med J* 2018;**108**:748. doi:10.7196/SAMJ.2018.v108i9.13073
5
6 506 28 Vallone D, Cantrell J, Bennett M, *et al.* Evidence of the Impact of the truth FinishIt
7 507 Campaign. *Nicotine Tob Res* 2018;**20**:543–51. doi:10.1093/ntr/ntx119
8
9 508 29 Alaqeel A, Kamalmaz H, Abou Al-Shaar H, *et al.* Evaluating the initial impact of the
10 509 Riyadh Epilepsy Awareness Campaign. *Epilepsy Behav* 2015;**52**:251–5.
11 510 doi:10.1016/j.yebeh.2015.09.010
12
13 511 30 Robson W, Beavis S, Spittle N. An audit of ward nurses' knowledge of sepsis. *Nurs Crit*
14 512 *Care* 2007;**12**:86–92. doi:10.1111/j.1478-5153.2007.00210.x
15
16 513 31 Gaieski D, Mikkelsen M, Band R, *et al.* Impact of time to antibiotics on survival in
17 514 patients with severe sepsis or septic shock in whom early goal-directed therapy was
18 515 initiated in the emergency department*. *Crit Care Med* 2010;**38**:1045–53.
19 516 doi:10.1097/CCM.0b013e3181cc4824
20
21 517 32 World Health Organization. Statement on maternal sepsis. Published Online First:
22 518 2017.<http://apps.who.int/iris/handle/10665/254608> (accessed 31 Mar 2017).
23
24 519 33 Cheng ER, Nelson CC, Leung-Strle P, *et al.* Nutrition provider confidence in the
25 520 Massachusetts Childhood Obesity Research Demonstration (MA-CORD) study. *Prev Med*
26 521 *Rep* 2019;**13**:289–92. doi:10.1016/j.pmedr.2019.01.010
27
28 522 34 Owens KM, Keller S. Exploring workforce confidence and patient experiences: A
29 523 quantitative analysis. *Patient Exp J* 2018;**5**:10.
30
31 524 35 Jabaley CS, Blum JM, Groff RF, *et al.* Global trends in the awareness of sepsis: insights
32 525 from search engine data between 2012 and 2017. *Crit Care Lond Engl* 2018;**22**:7.
33 526 doi:10.1186/s13054-017-1914-8
34
35 527 36 Savelkoel J, Claushuis TAM, van Engelen TSR, *et al.* Global impact of World Sepsis Day
36 528 on digital awareness of sepsis: an evaluation using Google Trends. *Crit Care* 2018;**22**.
37 529 doi:10.1186/s13054-018-1981-5
38
39 530 37 van Den Broek, Nynke, Ameh C, Madaj B, *et al.* Effects of emergency obstetric care
40 531 training on maternal and perinatal outcomes: a stepped wedge cluster randomised trial
41 532 in South Africa. *BMJ Glob Health* Published Online First: 2019. doi:10.1136/bmjgh-
42 533 2019-001670
43
44 534

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Countries eligible for the GLOSS 'STOP SEPSIS!' awareness campaign evaluation (N=46)
teal: countries included in the GLOSS STOP SEPSIS! awareness campaign evaluation (N=37);
green: countries eligible for the evaluation but from which 1 or less responses received for the evaluation
(N=9).




Figure 2. Measures of campaign exposure in percentages (N=1,033)




Figure 3. Responses when answering YES to the question "Did the information provided in the materials motivate you to do something differently than before?" (N=668). (Respondents were able to check as many response options as needed)

Appendix 1. Global Maternal Sepsis Study – Pre- and Post-Campaign Surveys

GLOSS Pre-Campaign Survey

This online survey is part of the activities set forth for a global study on maternal morbidity and mortality. This study is being conducted in approximately 50 countries across the globe, including your own, and it is coordinated by the World Health Organization and the healthcare facility where you work.

As part of this study, we want to learn more from healthcare providers about how you identify and manage women with complications during pregnancy, childbirth, postpartum, or post-abortion. The survey includes a number of questions on your knowledge, attitudes, and practices around maternal and neonatal health. This is not a test; this is an opportunity to let us know your thoughts and experience on the topic as a healthcare provider in one of the hospitals participating in the study.

This survey is voluntary, and your answers will be kept confidential, and you can choose whether to leave some questions unanswered. General information about you, your position, and geographical location will be collected to help us categorize respondents only but will not be used to identify you in particular. You are free to provide this information at the end of the survey.

After the study, and only if you agree, a second online survey will be sent to you via email. For this reason, we will ask you to provide an email address so that we can ensure delivery of the second survey. You will be free to decide to participate in this second survey too. Results of these surveys will be published in a peer-reviewed journal without attributing responses to any specific person or institution.

The completion of this survey implies your consent to participate.

If you have any question about the survey, please contact Ms Vanessa Brizuela (brizuelav@who.int)

I. Knowledge and attitudes

The following questions will ask that you respond according to your current role, competences, and skills depending on your training and background. That is, according to these, you may be the person triaging, prescribing, diagnosing, treating. Bear this in mind when responding.

1. What are the main conditions causing death and disability among women during pregnancy and/or childbirth in your hospital? Check all that apply [abortion-related complications, chronic/pre-existing disease, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other: please specify]
2. Case vignettes:

Case A: A 25-year-old 32-week pregnant woman comes to your facility brought by a family member saying she is feeling unwell. Her companion reports that she seems a bit disoriented and feverish. Without any further diagnostic testing or triaging:

 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials, ART), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
3. Case B: A recently pregnant woman comes to your facility complaining that she has abdominal pain and shortness of breath. Without any further diagnostic testing or triaging:
 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials, ART), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
4. How confident do you feel that you are capable of making the right decision in a case like the one above? [very confident, somewhat confident, neutral, not too confident, not confident at all]
5. How would you qualify the availability of resources in the facility where you work to help you make the right decisions? [always available, somewhat available, neutral, not always available, not available at all].
6. How supported do you feel by the facility in which you work to make the right decision in a case like the one above? [very supported, somewhat supported, neutral, not very supported, unsupported].
7. How well does this statement describe your facility: "The facility where I work doesn't let me handle cases like the one described above." [very well, somewhat well, indifferent, somewhat incorrectly, completely incorrectly]

- 1
2
3
4
5
6
7
8
9
10
8. Of the following, which do you think are the greatest barriers in making a right, and timely decision in your facility? Check up to two options. [I'm afraid of making a mistake, I've never seen cases like these, my supervisor doesn't let me make them, not sure I know the correct signs, we don't have a way to triage/treat/manage cases like these in my hospital, other]
 9. Does the hospital you work in have protocols in place for dealing with cases like the one described above? [yes/no/don't know]

11
12

DO NOT ALLOW GOING BACK AFTER THIS QUESTION

- 13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
10. Have you ever heard of the term maternal sepsis? [yes/no]
 11. If yes, how did you hear about this? Check all that apply [pre-service training, in-service training, public health campaign, colleagues, media (TV/radio/newspaper), other: please specify].
 12. What two criteria best describe maternal sepsis? Check two options [abnormal white cell count, altered mental status, elevated heart rate, excessively rapid respiration, fever, infection, low blood pressure, organ dysfunction, other]
 13. What supplies/commodities are essential to effectively identify sepsis among women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [blood culture, blood pressure apparatus, diagnostic imaging, laboratory (haematology/biochemistry), rapid test for infectious disease, serum lactate measurement, thermometer, urine output measurement, other]
 14. What supplies/commodities are essential to effectively manage sepsis in women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [antibiotics, blood transfusions, fluids, intensive care/high-dependency unit, other antimicrobials (e.g. antimalarials, ART), oxygen, urine output measurement, other]

34
35

II. Context

- 36
37
38
39
40
41
42
43
44
45
46
47
15. How many women are affected by maternal sepsis in your facility every year? Give your best estimate (a whole number), given your experience in the facility [Text box]
 16. How many neonates are affected by neonatal sepsis in the first week of life in your facility? Give your best estimate (a whole number), given your experience in the facility. [Text box]
 17. How many deliveries occur every year, on average, in your facility? Give your best estimate (a whole number). [Text box]
 18. Have you ever received specific training in how to manage women who present with signs of infection while pregnant, during childbirth, postpartum or post-abortion? [yes/no/can't remember]

48
49

III. Personal information

50
51
52

Remember! These data are collected for categorization purposes only. Your information is confidential and you will not be identified in any future publications on this study.

- 53
54
55
56
19. Age range
 20. Gender: [male, female, other]

- 1
2
3 21. Qualification: [nurse, midwife, physician/medical doctor, resident/physician in training,
4 community health worker, social worker, other: please specify].
5
6 22. Years of work experience in current setting: [years|months]
7
8 23. Total years of work experience (since completing your training): [number entry/2-digit max]
9
10 24. Place of work: [list of countries]
11
12 25. Location (of current or main place of work): [urban/rural]
13
14 26. Name of facility & address [Text box]
15
16 27. Facility type (of current or main place of work): [Clinic, Health centre, Maternity hospital,
17 Regional/Provincial hospital, District hospital, Other hospital, other]
18
19 28. Facility management (of current or main place of work): [private, public, social insurance,
20 NGO, other]
21
22 29. Did you participate in this year's World Sepsis Congress Spotlight on Maternal and Neonatal
23 Sepsis (held on 12 September 2017)? [yes/no]
24
25

26 **IV. Future contacts**

- 27
28 30. The global maternal study and awareness campaign would like to contact you at a future date
29 for a follow-up on this survey. If you agree to being contacted again, please provide us with
30 your email address.
31

32 Your contact details will be securely stored by the WHO staff person working on the study for one
33 year. You can contact us to modify or suppress your information at any time. To do so, please contact
34 Ms Vanessa Brizuela (brizuelav@who.int).
35

- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- I agree.
 - I do not agree

Please provide us with your email address [text box]

Thank you very much for participating in this survey! Your responses are extremely valuable to us in our efforts to improve the health of women and newborns.

GLOSS Post-Campaign Survey

This online survey is part of the activities set forth for a global study on maternal morbidity and mortality. This study is being conducted in approximately 50 countries across the globe, including your own, and it is coordinated by the World Health Organization and the healthcare facility where you work. As part of this study, we want to learn more from healthcare providers about how you identify and manage women with certain conditions during pregnancy, childbirth or postpartum or post- abortion.

A few months ago, you received a similar survey from us. At that point we asked that you provide us with an email address so that we could send you a follow-up questionnaire. We will ask again that you respond to a number of questions on your knowledge, attitudes, and practices around maternal and neonatal health. This is not a test; this is an opportunity to let us know your thoughts and experience on the topic as a healthcare provider in one of the hospitals participating in the study.

This survey is voluntary, and your answers will be kept confidential, and you can choose whether to leave some questions unanswered. General information about you, your position, and geographical location will be collected to help us categorize respondents only but will not be used to identify you in particular. You are free to provide this information at the end of the survey. Results of these surveys will be published in a peer-reviewed journal without attributing responses to any specific person or institution.

The completion of this survey implies your consent to participate.

If you have any question about the survey, please contact Ms Vanessa Brizuela (brizuelav@who.int)

I. General knowledge and attitudes

The following questions will ask that you respond according to your current role, competences, and skills depending on your training and background. According to these, you may be the person triaging, prescribing, diagnosing, treating. Bear this in mind when responding.

1. What are the main conditions causing death and disability among women during pregnancy and/or childbirth in your hospital? Check all that apply [abortion-related complications, chronic/pre-existing disease, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other: please specify]
2. Case vignettes:

Case A: A 25-year-old 32-week pregnant woman comes to your facility brought by a family member saying she is feeling unwell. Her companion reports that she seems a bit disoriented and feverish. Without any further diagnostic testing or triaging:

 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
3. Case B: A recently pregnant woman comes to your facility complaining that she has abdominal pain and shortness of breath. Without any further diagnostic testing or triaging:
 - a. What would you first think could be causing her to feel this way? Choose from the following list [abortion-related complications, embolism, haemorrhage, infection/sepsis, pre-eclampsia/eclampsia, other]
 - b. What would be the first two things this woman should receive? [antibiotics, blood transfusion, body fluid culture, fetal monitoring, fluids, haematology/biochemistry laboratory, other antimicrobials (i.e. antimalarials, ART), other laboratory test, other medication, oxygen, physical exam, urine output measurement, other]
4. How confident do you feel that you are capable of making the right decision in a case like the one above? [very confident, somewhat confident, indifferent/neutral, not too confident, not confident at all]
5. How would you qualify the availability of resources in the facility where you work to help you make the right decisions? [always available, somewhat available, indifferent/neutral, not always available, not available at all].
6. How supported do you feel by the facility in which you work to make the right decision in a case like the one above? [very supported, somewhat supported, neutral, not very supported, unsupported].
7. How well does this statement describe your facility: "The facility where I work doesn't let me handle cases like the one described above." [very well, somewhat well, indifferent/neutral, somewhat incorrectly, completely incorrectly]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
8. Of the following, which do you think are the greatest barriers in making a right, and timely decision in your facility? Check one option (the one most accurate to your situation). [not sure I know the correct signs, I'm afraid of making a mistake, my supervisor doesn't let me make them, we don't have a way to triage/treat/manage cases like these in my hospital, I've never seen cases like these, There are no barriers to making a right and timely decision in my facility, other]
 9. Does the hospital you work in have protocols in place for dealing with cases like the one described above? [yes/no/don't know]

14 DO NOT ALLOW GOING BACK AFTER THIS QUESTION

- 15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
10. Have you ever heard of the term maternal sepsis? [yes/no]
 11. If yes, how did you hear about this? Check all that apply [pre-service training, in-service training, colleagues, public health campaign, media (TV/radio/newspaper), other: please specify].
 12. What two criteria best describe maternal sepsis? Check two options [abnormal white cell count, altered mental status, elevated heart rate, excessively rapid respiration, fever, infection, low blood pressure, organ dysfunction, other]
 13. What supplies/commodities are essential to effectively identify sepsis among women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [blood culture, blood pressure apparatus, diagnostic imaging, laboratory (haematology/biochemistry), rapid test for infectious disease, serum lactate measurement, thermometer, urine output measurement, other]
 14. What supplies/commodities are essential to effectively manage sepsis in women during pregnancy, childbirth, postpartum or post-abortion? Check all that apply [antibiotics, blood transfusions, fluids, intensive care/high-dependency unit, other antimicrobials (e.g. antimalarials, ART), oxygen, urine output measurement, other]

37 **II. Context**

- 38
39
40
41
42
43
44
45
46
47
48
49
50
15. How many women are affected by maternal sepsis in your facility every year? Give your best estimate (a whole number), given your experience in the facility [Text box]
 16. How many neonates are affected by neonatal sepsis in the first week of life in your facility? Give your best estimate (a whole number), given your experience in the facility. [Text box]
 17. How many deliveries occur every year, on average, in your facility? Give your best estimate (a whole number). [Text box]
 18. Have you ever received specific training in how to manage women who present with signs of infection while pregnant, during childbirth, postpartum or post-abortion? [yes/no/can't remember]

51 **III. Campaign**

- 52
53
54
55
56
19. Did you notice any materials in your facility that related to maternal and neonatal sepsis? [yes/no] [if no go to question 27]

- 1
2
3 20. If yes, where did you see them? Check all that apply [labour ward, antenatal ward, postnatal
4 ward, emergency room/department, ICU/high dependency room, patient waiting area, other:
5 please specify]
6
7 21. If yes, what materials did you see? Check all that apply [informational posters about the study,
8 graphic materials with information about maternal sepsis, campaign website, social media,
9 press releases, none of the above].
10
11 a. Did you ever visit the website? [yes/no/N/A]
12 b. Did you ever tweet/re-tweet a message about the campaign? [yes/no/I don't use Twitter]
13 22. What were the main messages of these materials? Check all that apply ["stop sepsis", "think
14 sepsis", "right care, right now", "sepsis is life-threatening but when caught early and treated
15 promptly it can be stopped", "just ask, could it be sepsis?", "a world free of sepsis", "together,
16 we can stop maternal sepsis", "stop sepsis save lives", "surviving sepsis", none of the above]
17
18 23. Did you find the materials and messaging helpful? [yes/no]
19
20 a. If yes, why? Check all that apply [they provided information about maternal sepsis, they
21 invited me to act, they mentioned things I did not know, they helped explain the study to
22 me, they were visually appealing, they were in a language I could understand, other]
23 b. If no, why not? Check all that apply [they didn't provide any new information, I didn't
24 know what to do, the message was confusing, they were difficult to understand, they were
25 in a language I don't speak/read, they had too much text, they had too many images, the
26 colours didn't work in our hospital, they were unappealing, other]
27
28 24. Did the materials help you identify cases of women with infection or sepsis? [yes/no]
29
30 25. Did the information provided in the materials motivate you to do something differently than
31 before? [yes/no]
32
33 a. If yes, in what way? Check all that apply [to suspect maternal sepsis among women
34 presenting with specific signs, to act fast when I think a woman could have sepsis, to
35 implement health measures to prevent sepsis, to talk about sepsis with others, to learn
36 more about sepsis, other: please specify]
37 b. If no, why not? Please explain [text box]
38
39 26. In your opinion, did the materials help to increase awareness about maternal sepsis in your
40 facility? [yes/no]
41
42 27. Did you know that your facility participated in a global maternal sepsis study? [yes/no]
43
44 28. Did you know that your facility participated in an awareness campaign for the global
45 maternal sepsis study? [yes/no]
46

IV. Personal information

47 Remember! These data are collected for categorization purposes only. Your information is
48 confidential and you will not be identified in any future publications on this study.
49

- 50 29. Age range [18-25; 26-30; 31-40; 41-50; 51-60; 60+]
51 30. Gender: [male, female, other]
52 31. Qualification: [community health worker, midwife, nurse, physician/medical doctor,
53 resident/physician in training, social worker, student, physical therapist, auxiliary nurse,
54 other: please specify].
55
56

- 1
2
3 32. Years of work experience in current setting: [years | months]
4 33. Total years of work experience (since completing your training): [2-digit max]
5 34. Place of work: [list of countries]
6 35. Location (of current or main place of work): [urban/rural]
7 36. Name of facility and address [text entry]
8 37. Facility type (of current or main place of work): [Clinic, Health centre, Maternity hospital,
9 Regional/Provincial hospital, District hospital, Other hospital, other]
10 38. Facility management (of current or main place of work): [private, public, social insurance,
11 NGO, other]
12 39. Did you participate in the World Sepsis Congress Spotlight on Maternal and Neonatal Sepsis
13 (held on 12 September 2017)? [yes/no]
14
15
16
17

18 **V. Future contacts**

19
20 We might be interested in contacting you in the future with more information about this study or to
21 get further information about your responses to this survey. Please provide us with your email
22 address below if you agree with this.
23

- 24 I agree.
25 I do not agree
26

27 Your contact details will be securely stored by the WHO staff person working on the Global Maternal
28 and Neonatal Initiative for one year. You can contact us to modify or suppress your information at
29 any time. To do so, please contact Ms Vanessa Brizuela (brizuelav@who.int)
30
31

- 32 40. Please type your email address below [text entry]
33
34
35

36 Thank you very much for participating in this survey! Your responses are extremely valuable to us in
37 our efforts to improve the health of women and babies.
38

39 Please visit <http://srhr.org/sepsis> for more information about the study, the campaign, and maternal
40 sepsis.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Appendix 2. Respondent perception of enabling environments for maternal sepsis identification and management at pre- and post-campaign and changes after campaign implementation, limiting to most favourable responses (N=2,188)

	Pre-campaign n/N (%)	Post-campaign n/N (%)	Pre-post cOR [‡] [95% CI] [¶]	Percentage change %
<i>Perception of enabling environment for maternal sepsis identification and management</i>				
Very confident of making right decisions	390/1,155 (33.8)	395/1,033 (38.2)	1.21* [1.05-1.41]	13.2
Resources always available to make right decisions	443/1,155 (38.4)	386/1,033 (37.4)	0.96 [0.68-1.35]	-2.6
Very supported by facility in making right decisions	503/1,155 (43.6)	438/1,033 (42.4)	0.95 [0.67-1.37]	-2.6

cOR: crude odds ratio; CI: confidence interval; OR calculated clustering at the country level

Percentage change: [(% in post - % in pre)/% in pre]x100

**Refers to odds ratio between pre- and post-campaign; †reference group: pre-campaign; *p<0.05*

Responses were dichotomized as follows: a 1 was assigned to the most favourable response (i.e., they felt very confident about being capable of making the right decision) and a 0 to a combination of all the remaining options (i.e., somewhat confident, neutral, not very confident or not confident at all)

Appendix 3. Changes in respondent knowledge and perception of enabling environments after campaign

implementation among different sub-groups: [1] sample restricted to ≥ 1 response per facility at pre- and post-campaign; [2] sample restricted to ≥ 2 responses per facility at pre- and post-campaign; [3] sample restricted to countries with >30 responses at pre- or post-campaign

	Full sample (N=2,188)		Restricted sample ≥ 1 response per facility (N=1,872)		Restricted sample ≥ 2 responses per facility (N=1,645)		Restricted sample >30 responses per country (N=1,680)	
	Pre-post OR [‡] [95% CI] [†]	% change	Pre-post OR [‡] [95% CI] [†]	% change	Pre-post OR [‡] [95% CI] [†]	% change	Pre-post OR [‡] [95% CI] [†]	% change
<i>Knowledge on maternal sepsis</i>								
Have not heard of maternal sepsis	0.35* [0.18-0.68]	-63.4	0.36* [0.17-0.77]	-61.82	0.45* [0.22-0.93]	-53.58	0.34* [0.15-0.79]	-63.29
Correctly identified the two criteria to define maternal sepsis	0.67 [0.43-1.03]	-29.4	0.63 [0.39-1.01]	-33.19	0.57* [0.34-0.93]	-38.76	0.57* [0.33-0.98]	-39.46
Correctly identified management of sepsis when maternal sepsis was suspected	1.76 [0.73-4.21]	30.8	1.58 [0.58-4.30]	24.05	1.53 [0.51-4.62]	21.70	1.70 [0.51-5.72]	24.89
<i>Perception of enabling environment for maternal sepsis identification and management</i>								
Confident of making right decisions	1.44* [1.01-2.06]	7.3	1.36 [0.97-1.90]	6.39	1.33 [0.94-1.88]	6.34	1.45 [0.95-2.22]	7.99
Resources available to make right decisions	1.01 [0.68-1.49]	0.1	1.12 [0.76-1.66]	2.32	1.12 [0.72-1.74]	2.23	0.92 [0.57-1.50]	-1.62
Supported by facility in making right decisions	1.11 [0.80-1.54]	2.0	1.21 [0.84-1.73]	3.44	1.19 [0.81-1.76]	3.45	0.99 [0.69-1.44]	-0.11

OR: odds ratio; CI: confidence interval; percentage change = $[(\% \text{ in post} - \% \text{ in pre}) / \% \text{ in pre}] \times 100$

[‡]Refers to odds ratio between pre- and post-campaign, OR calculated clustering at the country level; [†]reference group pre-campaign; * $p < 0.05$

Appendix 4a. Changes in respondent knowledge after campaign implementation according to respondent and facility characteristics (N= 2,188)

Respondent characteristics	Had not heard about maternal sepsis					Correctly identified the two criteria to define maternal sepsis					Correctly identified management of sepsis when maternal sepsis was suspected							
	Pre-campaign (N=1,144)		Post-campaign (N=1,021)		OR [95% CI]†	% change	Pre-campaign (N=673)		Post-campaign (N= 647)		OR [95% CI]†	% change	Pre-campaign (N=251)		Post-campaign (N=239)		OR [95% CI]†	% change
	n	%	N	%		%	n	%	n	%		%	n	%	n	%		%
Overall	95	8	31	3	0.35* [0.23-0.52]	-63.4	109	16	74	11	0.67 [0.43-1.03]	-29.4	114	45	142	59	1.76 [0.73-4.21]	30.8
Qualification	1,141		1,013				670		645				250		235			
Nurse/midwife	74	17	16	4	0.18* [0.10-0.33]	-79.2	14	6	8	3	0.48 [0.20-1.14]	-50.3	24	28	41	46	2.13 [0.53-8.47]	61.3
Physician	16	3	10	2	0.77 [0.26-2.31]	-22.6	72	21	55	19	0.87 [0.55-1.38]	-10.3	55	50	75	67	2.06* [1.09-3.91]	35.1
Resident	4	3	4	4	1.36 [0.13-14.31]	34.3	23	27	11	15	0.48 [0.11-2.11]	-44.4	34	63	25	76	1.84 [0.49-6.90]	20.3
Years of experience	1,098		963				642		607				242		229			
<10	20	4	14	3	0.79 [0.28-2.24]	-19.9	58	18	32	11	0.54 [0.28-1.02]	-41.3	67	48	72	58	1.50 [0.40-5.58]	21.2
10-20	36	10	8	3	0.22* [0.10-0.50]	-75.9	28	15	24	12	0.76 [0.44-1.33]	-21.0	31	47	44	66	2.16* [1.04-4.49]	39.8
>20	26	12	4	2	0.17* [0.08-0.38]	-81.0	22	16	16	16	0.95 [0.53-1.69]	-4.4	13	37	21	57	2.22 [0.72-6.87]	52.8
Region	1,144		1,021				673		647				251		239			
Africa	14	6	4	2	0.27* [0.15-0.49]	-71.6	18	15	19	15	1.04 [0.46-2.31]	3.1	30	53	46	69	1.97 [0.95-4.08]	30.5
Asia	11	7	9	5	0.83 [0.25-2.76]	-15.7	7	5	7	6	1.06 [0.42-2.65]	5.7	4	14	8	23	1.85 [0.37-9.21]	65.8
Eastern Mediterranean	58	44	13	8	0.16* [0.09-0.31]	-81.7	2	3	8	9	3.19 [1.04-9.78]	200.0	2	12	10	45	6.25 [0.88-44.14]	286.5
Europe‡	7	5	2	2	0.39 [0.07-2.23]	-59.7	27	38	12	27	0.63* [0.41-0.96]	-27.3	5	12	4	27	1.60 [0.77-3.33]	126.8
Latin America	5	1	3	1	0.72 [0.07-7.77]	-27.9	55	20	28	11	0.49 [0.22-1.08]	-45.8	73	12	74	74	1.87 [1.17-20.42]	529.3

Country implemented an expanded version of campaign	1,144	1,021	673	647	251	239												
Yes	74	11	13	3	0.23* [0.16-0.32]	-75.2	75	19	37	12	0.58 [0.32-1.05]	-37	92	53	105	76	2.77 [0.88-8.69]	42
No	21	5	18	3	0.71 [0.35-1.45]	-27.6	34	12	37	11	0.89 [0.52-1.53]	-10	22	28	37	38	1.50 [0.51-4.40]	32
Respondent worked in a level III facility	1,144	1,021	673	647			251	239										
Yes	23	3	16	3	0.91 [0.38-2.18]	-8.5	87	18	58	15	0.80 [0.45-1.41]	-17.1	104	51	108	65	1.77 [0.51-6.10]	27.0
No	72	20	15	4	0.15* [0.08-0.28]	-82.3	22	11	16	6	0.51 [0.25-1.03]	-46.3	10	21	34	47	3.31* [1.54-7.12]	123.6

[#]Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan)

OR: odds ratio, OR calculated clustering at the country level; CI: confidence interval; Percentage change= [(% in post - % in pre)/% in pre]x100

[†]Reference group: pre-campaign

Where n represents the frequency and N the denominator (i.e. n= the number of respondents with a specific characteristic who answered correctly, N= the total number of persons who answered that question)

Appendix 4b. Changes in respondent perception of enabling environments after campaign implementation according to respondent and facility characteristics

Respondent characteristic	Confident of making right decisions					Resources available to make right decisions					Supported by facility in making right decisions							
	Pre-campaign (N=1,155)		Post-campaign (N=1,033)		OR [95% CI] †	% change	Pre-campaign (N=1,155)		Post-campaign (N=1,033)		OR [95% CI] †	% change	Pre-campaign (N=1,155)		Post-campaign (N=1,033)		OR [95% CI] †	% change
	n	%	n	%			n	%	n	%			N	%	n	%		%
Overall	897	78	861	83	1.44* [1.01-2.06]	7.3	909	79	814	79	1.01 [0.68-1.49]	0.1	921	80	840	81	1.11 [0.80-1.54]	2.0
Qualification	1,151		1,025				1,151		1,025				1,151		1,025			
Nurse/midwife	355	81	371	81	1.05 [0.56-1.96]	0.8	356	81	336	74	0.66 [0.34-1.28]	-8.9	367	83	347	76	0.63* [0.41-0.98]	-8.8
Physician	440	78	395	87	1.78* [1.23-2.57]	10.4	445	79	387	85	1.46* [1.17-1.82]	7.0	448	80	393	86	1.57* [1.12-2.22]	7.9
Resident	100	67	87	77	1.67 [0.97-2.88]	15.5	105	70	86	76	1.37 [0.77-2.42]	8.7	104	69	95	84	2.33* [1.24-4.38]	21.3
Years of experience	1,107		970				1,107		970				1,107		970			
<10	409	76	389	82	1.44 [0.99-2.10]	8.1	416	77	379	80	1.17 [0.80-1.73]	3.6	424	78	390	82	1.25 [0.86-1.83]	4.5
10-20	284	81	264	83	1.08 [0.73-1.59]	1.4	277	79	239	75	0.77 [0.52-1.13]	-5.9	280	80	248	78	0.85 [0.59-1.23]	-3.4
>20	179	82	160	92	2.43* [1.13-5.21]	11.5	187	86	153	88	1.17 [0.72-1.91]	2.0	188	87	158	91	1.52 [0.93-2.49]	4.8
Region	1,155		1,033				1,155		1,033				1,155		1,033			
Africa	189	84	198	88	1.31 [0.76-2.26]	3.8	158	71	157	69	0.95 [0.73-1.24]	-1.5	176	79	173	77	0.89 [0.63-1.26]	-2.6
Asia	128	74	145	85	2.04* [1.17-3.55]	15.3	134	77	150	88	2.18* [1.72-2.76]	13.9	137	79	151	89	2.09* [1.59-2.74]	12.2
Eastern Mediterranean	131	77	115	70	0.70* [0.64-0.77]	-9.0	109	64	84	51	0.59* [0.49-0.71]	-20.1	108	63	97	59	0.83 [0.61-1.14]	-6.9
Europe‡	97	71	77	79	1.59 [0.89-2.82]	12.1	112	82	83	86	1.32 [0.80-2.20]	4.7	112	82	88	91	2.18* [1.54-3.09]	11.0
Latin America	352	78	326	87	1.85* [1.14-3.01]	11.1	396	88	340	91	1.32 [0.68-2.57]	3.0	388	86	331	88	1.20 [0.59-2.44]	2.4

Country implemented an expanded version of campaign	1,155				1,033				1,155				1,033				1,155				1,033			
Yes	531	75	398	80	1.28 [0.76-2.15]	5.7	554	79	375	75	0.82 [0.45-1.48]	-4.6	567	80	391	78	0.87 [0.53-1.43]	-2.8						
No	366	81	463	87	1.52* [1.00-2.29]	6.8	355	79	439	82	1.25 [0.83-1.89]	4.4	354	79	449	84	1.45* [1.03-2.05]	7.1						
Respondent worked in a level III facility	1,155				1,033				1,155				1,033				1,155				1,033			
Yes	608	77	508	83	1.51* [1.10-2.05]	8.4	646	82	516	85	1.24 [0.85-1.79]	3.6	640	81	518	85	1.33 [0.95-1.87]	5.0						
No	289	79	353	83	1.31 [0.77-2.22]	5.1	263	72	298	70	0.92 [0.62-1.36]	-2.5	281	77	322	76	0.94 [0.71-1.25]	-1.4						

#Includes countries in Central Asia (Kazakhstan, Kyrgyzstan, and Tajikistan)

OR: odds ratio, OR calculated clustering at the country level; CI: confidence interval; Percentage change= $[(\% \text{ in post} - \% \text{ in pre})/\% \text{ in pre}] \times 100$

†Reference group: pre-campaign

Where n represents the frequency and N the denominator (i.e. n= the number of respondents with a specific characteristic who answered correctly, N= the total number of persons who answered that question)